{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Effectiveness of a web-based intervention for individuals who\n",
    "\n",
    "committed sexual offenses against children: a concealed, prospective, parallel group, placebo-controlled, randomized trial in Germany.\n",
    "\n",
    "Peter Fromberger [![](data:image/png;base64,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)](https://orcid.org/0000-0002-4818-8730) (Clinic for Psychiatry and Psychotherapy – Forensic Psychiatry, University Medical Center Göttingen)  \n",
    "Sonja Schröder [![](data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABAAAAAQCAYAAAAf8/9hAAAAGXRFWHRTb2Z0d2FyZQBBZG9iZSBJbWFnZVJlYWR5ccllPAAAA2ZpVFh0WE1MOmNvbS5hZG9iZS54bXAAAAAAADw/eHBhY2tldCBiZWdpbj0i77u/IiBpZD0iVzVNME1wQ2VoaUh6cmVTek5UY3prYzlkIj8+IDx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iIHg6eG1wdGs9IkFkb2JlIFhNUCBDb3JlIDUuMC1jMDYwIDYxLjEzNDc3NywgMjAxMC8wMi8xMi0xNzozMjowMCAgICAgICAgIj4gPHJkZjpSREYgeG1sbnM6cmRmPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj4gPHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9IiIgeG1sbnM6eG1wTU09Imh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC9tbS8iIHhtbG5zOnN0UmVmPSJodHRwOi8vbnMuYWRvYmUuY29tL3hhcC8xLjAvc1R5cGUvUmVzb3VyY2VSZWYjIiB4bWxuczp4bXA9Imh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8iIHhtcE1NOk9yaWdpbmFsRG9jdW1lbnRJRD0ieG1wLmRpZDo1N0NEMjA4MDI1MjA2ODExOTk0QzkzNTEzRjZEQTg1NyIgeG1wTU06RG9jdW1lbnRJRD0ieG1wLmRpZDozM0NDOEJGNEZGNTcxMUUxODdBOEVCODg2RjdCQ0QwOSIgeG1wTU06SW5zdGFuY2VJRD0ieG1wLmlpZDozM0NDOEJGM0ZGNTcxMUUxODdBOEVCODg2RjdCQ0QwOSIgeG1wOkNyZWF0b3JUb29sPSJBZG9iZSBQaG90b3Nob3AgQ1M1IE1hY2ludG9zaCI+IDx4bXBNTTpEZXJpdmVkRnJvbSBzdFJlZjppbnN0YW5jZUlEPSJ4bXAuaWlkOkZDN0YxMTc0MDcyMDY4MTE5NUZFRDc5MUM2MUUwNEREIiBzdFJlZjpkb2N1bWVudElEPSJ4bXAuZGlkOjU3Q0QyMDgwMjUyMDY4MTE5OTRDOTM1MTNGNkRBODU3Ii8+IDwvcmRmOkRlc2NyaXB0aW9uPiA8L3JkZjpSREY+IDwveDp4bXBtZXRhPiA8P3hwYWNrZXQgZW5kPSJyIj8+84NovQAAAR1JREFUeNpiZEADy85ZJgCpeCB2QJM6AMQLo4yOL0AWZETSqACk1gOxAQN+cAGIA4EGPQBxmJA0nwdpjjQ8xqArmczw5tMHXAaALDgP1QMxAGqzAAPxQACqh4ER6uf5MBlkm0X4EGayMfMw/Pr7Bd2gRBZogMFBrv01hisv5jLsv9nLAPIOMnjy8RDDyYctyAbFM2EJbRQw+aAWw/LzVgx7b+cwCHKqMhjJFCBLOzAR6+lXX84xnHjYyqAo5IUizkRCwIENQQckGSDGY4TVgAPEaraQr2a4/24bSuoExcJCfAEJihXkWDj3ZAKy9EJGaEo8T0QSxkjSwORsCAuDQCD+QILmD1A9kECEZgxDaEZhICIzGcIyEyOl2RkgwAAhkmC+eAm0TAAAAABJRU5ErkJggg==)](https://orcid.org/0000-0002-4140-1818) (Massregelvollzugszentrum Niedersachsen)  \n",
    "Bruno Siegel (Clinic for Psychiatry and Psychotherapy – Forensic Psychiatry, University Medical Center Göttingen)  \n",
    "Andreas Leha (Scientific Core Facility for Medical Biometry and Statistical Bioinformatics, University Medical Center Göttingen)  \n",
    "Fabian Kück [![](data:image/png;base64,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)](https://orcid.org/0000-0002-8634-9101) (Scientific Core Facility for Medical Biometry and Statistical Bioinformatics, University Medical Center Göttingen)  \n",
    "Louisa Neumann (Clinic for Forensic Psychiatry and Psychotherapy, KRH Psychiatry Wunstorf)  \n",
    "Safiye Tozdan [![](data:image/png;base64,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)](https://orcid.org/0000-0001-6645-3617) (Institute for Sex Research, Sexual Medicine & Forensic Psychiatry, Center for Psychosocial Medicine, University Medical Center Hamburg-Eppendorf)  \n",
    "Sabine Horn (Criminal Law, Criminal Procedure, and Criminal Policy, University of Cologne)  \n",
    "Claudia Buntrock (Institute of Social Medicine and Health Systems Research (ISMHSR), Otto-von-Guericke-University Magdeburg)  \n",
    "Kirsten Jordan [![](data:image/png;base64,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)](https://orcid.org/0000-0001-8083-5857) (Clinic for Psychiatry and Psychotherapy – Forensic Psychiatry, University Medical Center Göttingen)  \n",
    "Martin Rettenberger (Centre for Criminology)  \n",
    "Sonja Etzler (Centre for Criminology)  \n",
    "Anja Schiemann (Criminal Law, Criminal Procedure, and Criminal Policy, University of Cologne)  \n",
    "Peer Briken [![](data:image/png;base64,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)](https://orcid.org/0000-0002-1360-014X) (Institute for Sex Research, Sexual Medicine & Forensic Psychiatry, Center for Psychosocial Medicine, University Medical Center Hamburg-Eppendorf)  \n",
    "Jürgen Leo Müller (Clinic for Psychiatry and Psychotherapy – Forensic Psychiatry, University Medical Center Göttingen)  \n",
    "December 14, 2025\n",
    "\n",
    "<span class=\"wordcount-title\">Metrics</span>\n",
    "\n",
    "<span class=\"word-count-item\">**Summary**: ??? words (300 max); **Manuscript**: 13057 words (3.500 max); **Supplement**: 5 words (no limit); **References**: 0 words (30 citations max).</span>"
   ],
   "id": "13a9431b-359b-46fa-b8eb-c668400ab953"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- SUMMARY -->"
   ],
   "id": "64769acc-15a2-4b8d-bd8e-72dd674b03fc"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- Is automatically filled with metadata defined above; do not delete the shortcode -->"
   ],
   "id": "cf6c79a4-d91f-4a86-a2b9-b997b1946e9f"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- We do not count the words in the summary -->"
   ],
   "id": "0396a475-57a3-469e-9e08-b1f4b7e47c83"
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Summary\n",
    "\n",
    "### Background\n",
    "\n",
    "Sexual offenders often present with diverse risk profiles requiring differentiated interventionsknuth84?.\n",
    "\n",
    "### Methods\n",
    "\n",
    "We conducted a randomized controlled trial evaluating a web-based relapse prevention tool. The trial was prospectively registered on April 24, 2020 in the German Clinical Trial Register (DRKS00021256).\n",
    "\n",
    "### Findings\n",
    "\n",
    "Preliminary findings suggest significant reductions in dynamic risk factors.\n",
    "\n",
    "### Interpretations\n",
    "\n",
    "Taken together, the intervention did not lead to measurable changes in the primary CARES outcome but was associated with selected improvements in secondary endpoints — most notably reduced explicit sexual interest and strengthened working alliance with coaches and supervisors — without indications of harm also for low-risk individuals.\n",
    "\n",
    "### Funding\n",
    "\n",
    "The work was funded by the German Federal Ministry of Education and Research (BMBF, Funding number: 01KR1807A). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report."
   ],
   "id": "03cbbd63-b978-4f20-9fc6-c7977878a221"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- Example figure -->"
   ],
   "id": "d5af726a-bff7-4e3d-a03b-be0d139e4780"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<img width=\"100%\" src=\"resources/figures/mtDiagrams-sd_guided_tasks.png\" />"
   ],
   "id": "592d74b9-24d9-4bc2-85b7-40b49c3afe02"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- INTRODUCTION SECTION -->"
   ],
   "id": "493e0680-19cf-49a3-a5cc-f27f6c823e4b"
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Introduction\n",
    "\n",
    "Child sexual abuse (CSA), hands-on as well as hands-off offenses like the use of Child Sexual Abuse Material (CSAM), constitutes one of the most severe adverse experiences in child development<sup>[1](#ref-worldhealthorganizationRespondingChildrenAdolescents2017)</sup>. Recently, a meta-analysis found lifetime prevalence rates of 11.4% for sexual harassment and 8.7% for any form of hands-on sexual violence<sup>[2](#ref-piolantiGlobalPrevalenceSexual2025)</sup>. Beyond its profound short- and long-term consequences for survivors, CSA represents a substantial challenge for society due to high economical costs<sup>[3](#ref-kewleyPreventingChildSexual2023)</sup>. These figures clearly demonstrate the importance of preventing CSA or the use of CSAM."
   ],
   "id": "4a037c83-c29d-45cf-b754-9bf8de62f20d"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- PANEL -->"
   ],
   "id": "738e41d2-4f97-49de-a589-07ccc35c48a6"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- Is automatically filled with metadata defined above; do not delete the shortcode -->"
   ],
   "id": "ea9a8a59-a063-460f-8445-5d1162b534d3"
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<span class=\"panel-main-title\">Research in context</span>\n",
    "\n",
    "<span class=\"panel-section-title evidence-before\">Evidence before this study</span>\n",
    "\n",
    "This section should include a description of all the evidence that the authors considered before undertaking this study. Authors should state: the sources (databases, journal or book reference lists, etc) searched; the criteria used to include or exclude studies (including the exact start and end dates of the search), which should not be limited to English language publications; the search terms used; the quality (risk of bias) of that evidence; and the pooled estimate derived from meta-analysis of the evidence, if appropriate. Research in context panels should not have references; anything mentioned that needs referencing should appear in the main text.\n",
    "\n",
    "<span class=\"panel-section-title added-value\">Added value of this study</span>\n",
    "\n",
    "Authors should describe here how their findings add value to the existing evidence (including an updated meta-analysis, if appropriate).\n",
    "\n",
    "<span class=\"panel-section-title implications\">Implications of all the available evidence</span>\n",
    "\n",
    "Authors should state the implications for practice or policy and future research of their study combined with existing evidence.\n",
    "\n",
    "In CSA prevention, a distinction is commonly drawn between primary, secondary, and tertiary treatment programs. Primary prevention initiatives are directed at children and their parents, whereas secondary prevention programs seek to engage adults identified as being at risk for sexual child offenses, but have not yet been convicted. Tertiary programs have the longest history and are designed for individuals who committed sexual offenses against children and have been convicted for their offenses<sup>[3](#ref-kewleyPreventingChildSexual2023)</sup>. In recent years, secondary treatment approaches have been promoted and in the last few years more and more secondary prevention programs have been implemented worldwide<sup>[4](#ref-setoEvaluatingChildSexual2024)</sup>. However, in a recent meta-analysis,<sup>[4](#ref-setoEvaluatingChildSexual2024)</sup> identified only five publications exploring the effectiveness of secondary prevention programs for adults, none of them a randomized clinical trial. Besides too low sample sizes and the lack of adequate control groups, most of these studies did not provide data on the number of re-offenses based on criminal records<sup>[3](#ref-kewleyPreventingChildSexual2023)</sup>. Recently<sup>[5](#ref-beierPreventingChildSexual2024)</sup> published data on self-reported recidivism rates based on a sample of n = 56 individuals diagnosed with pedophilic or hebephilic disorder (26.8% already known to the justice system and 16.1% had no sexual offenses in their history before treatment) who finished the secondary prevention program. In a 1-11 years follow up, 7.7% of participants of the prevention program with a history of CSA had re-offended, whereas 89.1% of previous exclusive CSAM users reported recidivism. The authors reported no data on adequate control groups nor recidivism rates based on criminal records. Compared to recidivism rates for CSAM-exclusive user of 4.1% based on official records (38.3% based on self-reports;<sup>[6](#ref-baskurtMetaanalysisRecidivismRates2024)</sup>), the effectiveness of secondary treatment program Dunkelfeld project has been questioned<sup>[9](#ref-beierPreventingChildSexual2025)</sup>. In summary, currently it is not possible to draw meaningful conclusions on the effectiveness of secondary treatment programs, especially due to a lack of methodological adequate studies<sup>[4](#ref-setoEvaluatingChildSexual2024)</sup>. The effectiveness of tertiary treatment programs for individuals who already committed CSA or used CSAM has been studied more extensively. A recent meta-meta-analysis (MMA) and meta-analysis demonstrated that cognitive-behavioral treatment programs based on the Risk-Need-Responsivity model<sup>[10](#ref-andrewsPsychologyCriminalConduct2010)</sup> are most effective in reducing re-offenses of individuals who have sexually offended. Across meta-analysis, there is consistent evidence for a small but stable treatment effect<sup>e.g.\\ [11](#ref-holperModeratorsSexualRecidivism2024),[12](#ref-koehlerMetaevaluativeSynthesisEffects2025)–[15](#ref-schmuckerSexualOffenderTreatment2017)</sup>. In their recent MMA of 21 meta-analyses on tertiary treatment programs,<sup>[**OlverSexualOffenseTreatment2025?**](#ref-OlverSexualOffenseTreatment2025)</sup> reported a treatment effect with an odds ratio (OR) of 0.67, indicating that participants in tertiary treatment programs exhibited approximately a 33% lower risk of recidivism relative to controls. The meta-analyses identified several moderator variables: community treatment programs provide higher effect-sizes than institutional treatment programs; individual treatment programs show higher effect-sizes than group programs, high-intensity programs are more effective than low-intensity programs, and the higher the design quality of the study, the lower the effect size<sup>[11](#ref-holperModeratorsSexualRecidivism2024),[13](#ref-olverSexualOffenseTreatment2025)</sup>. Up to now, most of the mentioned meta-analyses only report on tertiary treatment programs for individuals who have been convicted for CSA. The figure for individuals who have used CSAM is not as well studied. Since the world wide web is more and more accessible and CSAM is more and more in the focus of the law enforcement agencies, the number of individuals convicted for the use of CSAM is arising worldwide<sup>[6](#ref-baskurtMetaanalysisRecidivismRates2024)</sup>. A recent review shed light on the methodological weakness of existing studies on the effectiveness of prevention programs for individuals who have used CSAM: mostly, the studies suffer from small sample sizes, to short follow-up periods and self-reports as main outcome. Besides these limitating factors, the meta-analysis demonstrated preliminary support for the effectiveness of these programs<sup>[16](#ref-gouveiaSystematicReviewEffectiveness2025)</sup>. To sum up, meta-analyes demonstrate a broad empirical basis for a small but significant effectiveness in reducing recidivism of tertiary prevention programs for individuals sentenced for CSA. For individuals who used CSAM and for secondary prevention programs, the empirical proof of effectiveness is still pending. It has been assumed, that one reason for small effect-sizes with regard to individuals used CSAM is the fact, that most included prevention programs have been initially designed for CSA but not for CSAM-exclusive offenses<sup>[4](#ref-setoEvaluatingChildSexual2024)</sup>.\n",
    "\n",
    "### Treatment targets: risk factors for recidivism\n",
    "\n",
    "To achieve a reduction in re-offenses, it seems to be most promising to target dynamic factors, which are changeable and strong associated with recidivism<sup>[17](#ref-setoEmpiricallybasedDynamicRisk2023)</sup>.<sup>[18](#ref-mannAssessingRiskSexual2010)</sup> introduced the term meaningful psychological risk factors for sexual offending by identifying those risk factors in the literature, which are dynamic and therefore changeable by treatment and are empirically proved in enhancing the risk for recidivism. Recently,<sup>[17](#ref-setoEmpiricallybasedDynamicRisk2023)</sup> replicated the findings of Mann et al. and proofed the meaningful risk factors with a broader and more recent literature basis. Meaningful risk factors can be sorted into four risk domains, which are defined by concrete dynamic risk variables: (1) Atypical sexuality umfasst sexual preoccupation and paraphilic sexual interests; (2) Self-regulation problems, defined as impulsivity, lifestyle instability and emotion regulation deficits; (3) antisocial cognitions like offense-supportive attitudes and beliefs, hostile masculinity and non-compliance with interventions; and (4) relationship problems, defined as a low capacity for adult intimacy, existing emotional congruence with children, and negative social influences (see also @tbl-sec-outcomes). The emprirical basis for risk factors for CSAM-exclusive offences is not as broad as for sexual offending in the sense of in-person offences.<sup>[19](#ref-babchishinChildSexualExploitation2018)</sup> elaborated in their review risk factors for CSEM-exclusive offenders. Atypical sexual interests, sexual pre-occupation, sexual arousal, access to the internet and children, and distorted cognitions are assumed to play a key role in recidivism. Thus, there is a overlap between risk factors for CSA offenses and risk factors for CSAM offenses<sup>[20](#ref-reichelReviewRiskFactors2024)</sup>. But it is assumed, that e.g. the content of offense-supportive attitudes differs from the content of offense-supportive attitudes for mixed offenders or CSA-exclusive offenders. Access to children or the internet is a so-called facilitating factor in the sense of the Motivation-Facilitation Model of sexual offending and therefore only indirect changeable by treatment<sup>[21](#ref-setoMotivationFacilitationModelSexual2019)</sup>. Some of the dynamic risk assessment tools developed for hands-on and mixed offenders seems to be also valid for CSAM-exclusive offenders, also highlighting the overlap of risk factors<sup>[22](#ref-babchishinACUTE2007STABLE2007Predict2023)</sup>. On the other side, forementioned small treatment effects for CSAM-exclusive offenders may reflect the fact, that some specific risk variables are not considered in an sufficient amount in current prevention programs.\n",
    "\n",
    "Two main theoretical frameworks behind treatment programs can be identified: the RNR framework and the GLM framework \\[LIT\\]. Both frameworks address the same risk factors but with different therapeutical haltungen as well as different techniques (e.g. DBT elements, etc.) and from a practioniar point of view, most programs seems to be eklektik….The same seems to be true for treatment programs for CSA and CSAM: slightly different contents but all treatment programs addressing the same risk factors…..\n",
    "\n",
    "### Gaps in Post-Release Care\n",
    "\n",
    "Besides the above mentioned encouraging small but stable treatment effect of tertiary treatment programs, there exists a care gap in the treatment of CSA and CSAM offenders originating from only having few possibilities of community-based treatment and an increase of convicted ISAC and ICCSEM under community supervision within the last years: For example,<sup>[23](#ref-schmidtOutpatientTherapistsPerspectives2022)</sup> showed that 63% of n = 427 Swiss outpatient therapists working in the primary healthcare system are unwilling to provide treatment for individuals who have a sexual interest in children and have already been convicted. The study further underlines, that the unwillingness to treat those patients is correlated with stigmatizing attitudes and not feeling to be competent enough. In a German sample,<sup>[24](#ref-stiels-glennAvailabilityOutpatientPsychotherapy2010)</sup> showed that, 87% of included psychotherapists are not willing to provide treatment, whereas only 2.7% would do so. Furthermore, most of the above mentioned secondary prevention programs, do (at least officially) not accept already convicted ISAC and ICCSEM under CS for treatment<sup>[25](#ref-beierGermanDunkelfeldProject2015)</sup>. Additionally to this unwillingness of professionals to treat individuals who have abused a child or consumed child abusive material, the number of individuals convicted for the use of child abusive material, rised in the last years resulting in a increased demand for treatment. In consequence, even if the court ordered treatment, many of convicted ISAC and ICCSEM under CS have difficulties to receive professional treatment during community supervision, especially in rural areas. One possible solution to close this gap may be the use of a digital health intervention (DHI)<sup>[26](#ref-hillertWebBasedInitiativesPrevent2024),[27](#ref-wildWebBasedHealthServices2019)</sup>.\n",
    "\n",
    "### Webbased interventions\n",
    "\n",
    "Digital health interventions (DHIs) are assumed to be able to provide a greater accessibility for individuals who face challenges in availing mental health services owing to limited availability or stigma associated with seeking help resulting in reaching a wider population as it is possible with in-face interventions (IFIs). Additionally, DHIs are assumed to be more cost-effective with greater flexibility for clinicians as well as patients compared to IFIs. Meta-analytics demonstrate support for the effectiveness of DHIs compared with active interventions for schizophrenia spectrum disorders, major depressive disorder, social anxiety disorder, and panic disorder. Notable treatment effects compared with a waiting list were also observed for specific phobias, generalized anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, and bulimia nervosa. The data base and number of high-qualitative RCTs differ between the different mental health disorders, the implementation of DHIs is recommended as a tool to bridge the gap in care for individuals on waiting lists<sup>[28](#ref-crocamoDigitalHealthInterventions2025)</sup>. Meta-analysis demonstrated that stand-alone web-based interventions with guidance tend to have greater effect sizes than web-based interventions without professional assistance. Webbased interventions with professional assistance showed smaller attrition rates, a higher number of completed modules, and larger symptom reduction in users suffer from, e.g., depression, anxiety disorders, and eating disorders<sup>[29](#ref-baumeisterImpactGuidanceInternetbased2014)–[33](#ref-richardsComputerbasedPsychologicalTreatments2012)</sup>. Despite the qualitative and quantitative reduction of overall therapeutic contact in web-based interventions (e.g., absence of social and non-verbal signals), studies seem to indicate that a comparable perceived quality of the therapeutic alliance can be achieved as in in-face settings<sup>[34](#ref-anderssonTherapeuticAllianceGuided2012)–[36](#ref-bengtssonTherapistsExperiencesConducting2015)</sup>. It is assumed, that DHIs have also the potential to bridge the gap in the care of individuals with regard to tertiary prevention of individuals who have abused a child ore used CSAM<sup>[26](#ref-hillertWebBasedInitiativesPrevent2024),[27](#ref-wildWebBasedHealthServices2019)</sup>. To date, studies on the effectiveness of WBIs for individuals who committed CSA or CSEM offenses are scarce<sup>[26](#ref-hillertWebBasedInitiativesPrevent2024),[27](#ref-wildWebBasedHealthServices2019),[37](#ref-schroderWebBasedInterventionsIndividuals2023)</sup> .<sup>[37](#ref-schroderWebBasedInterventionsIndividuals2023)</sup> identified six web-based interventions (WBIs) already implemented in secondary prevention programs, but none implemented in tertiary treatment programs. Furthermore, only for one of these WBIs, a placebo-controlled clinical trial reported on the effectiveness of the WBI. In 2022,<sup>[38](#ref-latthEffectsInternetdeliveredCognitive2022)</sup> evaluated a guided WBI exclusively for individuals who commit CSEM offenses. The participants were recruited mainly via Darknet forums and could take part anonymously. The results showed that, compared with users of a psychological placebo WBI (n = 78), participants of the WBI Prevent It (n = 76) reported a statistically significant, but small decrease in weekly viewing of CSEM (d = .18 from pre to post; d = .20 from post to follow-up). Besides of some methodological weakness of this clinical trial<sup>[4](#ref-setoEvaluatingChildSexual2024)</sup>, it provides first preliminary support for the potential effectiveness of WBIs for CSEM<sup>[26](#ref-hillertWebBasedInitiativesPrevent2024)</sup>. For tertiary prevention, there exist no proof of effectiveness for WBIs.\n",
    "\n",
    "### Aim of the study\n",
    "\n",
    "In consequence, the study aimed to develop and provide a newly developed WBI to bridge the gap in post-release care of individuals, who have been sentenced for CSA or the use of CSAM. By doing so, the current RCT evaluates the effectiveness of the WBI in reducing dynamic risk factors for re-offending compared to a web-based placebo arm and to evaluate the individual effects of treatment modules within the web-based intervention on reducing dynamic risk factors based on self reports. The primary hypothesis constitutes that participants who take part in the web-based intervention show significantly lower values on dynamic risk factors from baseline to inter-, and post-treatment, compared to an web-based placebo intervention. Furthermore, we assumed that, in contrast to the placebo arm, each online module within the intervention arm will reduce the dynamic risk factors targeted in this module in a statistically significant manner."
   ],
   "id": "5ea6ff13-d957-434b-a5a0-24573cb752b9"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- METHODS SECTION -->"
   ],
   "id": "cd1ba7e9-d60c-40cf-8b5f-8101ce6f6666"
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Method\n",
    "\n",
    "### Patient and public involvement\n",
    "\n",
    "The project team was advised by a multidisciplinary team, including a police officer, a supervision officer, and a representative of patients during the clincal trial as well as during development of the HBI (meeting once a year).\n",
    "\n",
    "### Study design\n",
    "\n",
    "The trial follows a concealed, prospective, parallel group, placebo-control trial with 1:1 randomization at a single site in Germany (Human Medical Centre Göttingen, Göttingen). Due to ethical considerations, both treatment arms have been provided as an add-on to community supervision as Usual (CSaU). CSaU comprises all orders of the court and treatment as usual (e.g., in-face contacts with supervision officers, therapeutic treatment ordered by court, medical treatment) and ensures the necessary maßnahmen ordered by court to prevent society. This potential confounding variable has been reduced by adding additional psycho-therapeutical treatment and medical treatment as stratum. Data on re-offenses based on criminal records will be assessed in a five-year follow up and reported as soon as the data are available. The trial was prospectively registered on April 24, 2020 in the [German Clinical Trial Register (DRKS00021256)](https://drks.de/search/en/trial/DRKS00021256). The study design has been prospectively published<sup>[39](#ref-frombergerMyTabuAPlaceboControlled2021)</sup>. The report follows strictly the CONSORT guidelines for randomized trials<sup>[40](#ref-hopewellCONSORT2025Statement2025)</sup>.\n",
    "\n",
    "### Participants\n",
    "\n",
    "All sexual offenders under community supervision (§§56, 57, 68 StGB) from all German states with the exception of Hamburg, Bremen and Saarland, which are sentenced for at least one case of CSA (§§176 StGB) or CSAM (§184b StGB), were eligible for the trial. There exist no exclusion criteria regarding gender. Only persons who are older than 18 years are included. Exclusion criteria are (1) a probation period shorter than 6 months at enrollment, (2) no access to a PC, tablet or smart phone, (3) a severe acute psychiatric disorder (e.g., acute psychosis), (4) a severe cerebro-organic disorder, (5) a severe cognitive impairment, (6) withdrawal of the informed consent. All participants gave written informed consent. The participants were credited with monetary compensation after completing a session, which they could request as a voucher if they had saved €15 (or a multiple thereof). The total amount of compensation was €120 when all sessions were completed (one introductory session and 24 content sessions). However, the participants were told that they would not receive any confirmation of having met the treatment requirements set by the court by taking part in the clinical trial. The clinical trial protocol was approved by the medical ethical board of the University Medical Center Göttingen, Göttingen, Germany, on February 21, 2020 (reference number 16/2/20).\n",
    "\n",
    "### Randomisation and masking\n",
    "\n",
    "The clinical trial comprises two parallel groups (intervention group and placebo group). Subjects are randomly allocated to treatment using an allocation ratio of 1:1. The randomization lists are centrally generated using a computerized system (secuTrial®, interActive Systems GmbH, Germany), stratified by the offense type (§176 ff StGB vs. \\$184 b StGB), type of community supervision, external treatment in addition to community supervison as usual, and static risk to re-offend at baseline (assessed with the modified Static-99, LIT und genauere Erläuterungen noch ergänzen). At screening, each subject receives the next consecutive screening number. At randomization, each subject eligible for study participation receives the next consecutive randomization number according to his stratum from a block of randomization numbers (block size: 4). Due to security reasons, blinding of supervision officers (SOs) and supporting therapists was not possible. Nevertheless, subjects, outcome adjudicators, members of the data safety monitoring board (DSMB) and data analysts (observer) have been blinded until the end of the data analysis.\n",
    "\n",
    "### Procedures\n",
    "\n",
    "For the recruitment of participants, scientific staff informed community supervisors about the clinical trial and asked them to inform eligible individuals under their supervision. For eligible individuals, an individual meeting with an independent research assistant took place at the supervision office. During this meeting, the research assistant provided detailed information about the goals and procedure of the trial, data security and advantages or disadvantages of taking part in the trial. If the potential participant was further interested to take part, he or she received an information letter, the informed consent, an intervention agreement, and a letter releasing the supervision officer from the confidentiality obligation. In the intervention agreement, the participant agreed not to commit offenses during the participation and is informed that any violation could lead to exclusion. Furthermore, the research assistant performs the pre-intervention assessments \\[WELCHE?\\]. If a potential participant does not want to take part in the trial, he or she was asked for informed consent in filling out a questionnaire on reasons for not wanting (Questionnaire of Non Participating; QNP) as well as the questionnaires on demographic data. Further, the participant was asked for allowance to assess his or her officially registered re-offenses in a 5-years follow up. After obtaining the written informed consent, the intervention agreement, and the release from confidentiality, the participant was randomly allocated to one of the trial arms. After allocation, the username as well as the initial password necessary to log in was delivered by post to the supervision officer, who gave it to the participant at their next meeting. After the first log-in, the participant had to change the initial password due to security reasons. After changing the initial password, the participant had to go through an introduction, which explains the usage of the intervention website, before he or she can start with the first online module. The starting procedure for the placebo condition was the same as for the experimental condition. Also in both trial arms, the provided content was divided into six online modules. Each module was further divided into four sessions. Participants were advised to use the intervention regularly and work through one session per week. Before the first module and after each consecutive module, the specific pre-post Questionnaires for this module were provided within the app. Before each questionnaire, due to ethical reasons, the participant was informed if the his answers will be viewable by their community supervisor or not (this was the fact for all questionnaire items of the primary endpoint as well as the Mood and Risk Questionnaire, MRQ). Only if all questionnaires at a specific timepoint have been filled in and all guided tasks are revised by the online coach, the participant was able to start the first session of the next module. After the last session of each module and filling in post questionnaires, the participant has to wait one week in order to ensure a time difference between the post measurement of the last module and the pre measurement of the next module. This was not the fact after the last session of the last module (SEE TABLE XX FOR AN OVERVIEW OF MEASUREMENT TIMEPOINTS). Consequently, the intervention as well as the placebo arm consists of 4 modules, each of which can be completed in 29 weeks (24 weeks plus 5 weeks waiting time). Within each session, the participant was able to work on the lections in a self-paced manner. In cases where a participant completes all sections in under seven days, a mandatory waiting period was applied, requiring seven full days to elapse before commencement of the subsequent session. Furthermore, prior to progressing, all guided tasks must have been reviewed and formally marked as completed by the coach. The clinical trial ends for the individual participant if he has finished the content of the last section in module six and filled-in the post questionnaires at this timepoint. After finishing, the participants can log in one more week e.g. to download the individual digital first aid kit or to request the expense allowance. After this week, the account of the participant was closed and the participant has not further access to the HBI. To prematurely exclude a participant from the clinical trial, the supervision officer had to fill in a questionnaire on exclusion reasons (Exclusion Questionnaire, EQ) and the supervisor had to request the exclusion within the HBI. After receiving the request, the PI closed the access to the HBI for this participant.\n",
    "\n",
    "Due to pseudonymization and data security aspects, the trial staff (online coaches as well as scientific staff or PIs) had no possibility to contact a participant during the clinical trial directly. All communication with participants takes place within the app, communication with supervisors per Email, telephone or in presence. The supervisors of participants, who did not log in within the last four weeks, have been informed automatically about this fact by email and requested to ask the client about the reasons and to remind him to log-in on a regular basis. Also, six month before the end of the clinical trial, all supervisors have been pleased to inform their clients about the coming end of the clinical trial. Supervisors not logged in within the last month have been automatically reminded by Email.\n",
    "\n",
    "#### Aufbau und Struktur der HBI\n",
    "\n",
    "The HBI @myTabu consists of three isolated sections, one only for participants, one only for the coaches and one section only for supervisors. The access to these sections was secured by username and password to full-fill criteria of the DSGVO. On the landing page of the coach section, a dashboard informs the coach on tasks he has to perform (e.g. unanswered messages by a client, open guided tasks). Each coach had only access to the participants he was responsible for. The landing page links to the in-app messenger and a page for working on guided tasks together with the participant.\n",
    "\n",
    "The supervisor section, only accessible by participating community supervisors, provides a landing page which summarized important key aspects (treatment progress, critical events) of all participants, which have been supervised by this supervisor. Due to security reasons, the supervisor was able to see the raw values of the primary endpoint \\[UND NOCH VIEL MEHR\\]. If a item of the primary endpoint has been graded as a potential hint to recidivism by lawyers within the research team during development of the app, additional judicial information have been provided. Furthermore, each supervisor has to fill in a questionnaire at baseline about demographic and criminological characteristics of the participant as well as every four weeks during the course of the clinical trial of his client in order to assess changes from baseline.\n",
    "\n",
    "The structure and organization of the content were identical across both trial arms. At the beginning of each session, key elements from the previous session or module were recapped. At the end of each session, the most important points of that session or module were summarized. Content created during exercises was partly dynamic integrated in consecutive sessions. For example, at the start of the intervention participants created a list of positive activities, which was later used to suggest ways in which they could reward themselves for completing a session or module. In both trial arms, the program included digital psycho-educational blocks incorporating multimedia elements such as videos and graphics, as well as guided and unguided exercises. A total of eighteen different online exercises (e.g., fill‑in‑the‑gap tasks, multiple‑choice questions) were integrated into the HBI. These exercises were either offered as self‑guided tasks with automated feedback or as coach‑guided tasks in which feedback was provided by online coaches. In the intervention arm, the most relevant aspects of each session were delivered as guided tasks. In the placebo arm, the allocation of tasks as guided or unguided was determined based on a predefined matching procedure to replicate the distribution of guided and unguided tasks in the intervention arm. The feedback of the online coaches was manualized: Within a special section of the HBI, the coach was able to choose one out of XX pre-build answers for each guided task \\[BEARBEITUNG DER ÜBUNGEN UND WIE COACH FEEDBACK GAB GENAUER ERKLÄREN\\]. Furthermore, an in-app messaging system allowed the user to communicate in real-time with the online coach as well as the supervision officer. It was ensured that messages and feedback for guided tasks has been provided within 36 hours by the coach. Finally, an online first aid kit was provided for each user and filled with individual skills prepared by the user itself during guided tasks in the intervention arm. In the placebo arm, the first add kit was not individualized but pre-filled with basic hints. Throughout all modules, the speech was friendly, empathetic, simple, and easy to understand (e.g., no technical terms, examples of everyday life) in order to account for the different cognitive functioning level of participants.\n",
    "\n",
    "Im teilnehmerbereich wurden auf der landing page übersichtlich alle wichtigen Informationen dargeboten (wie man weiter machen kann, ob noch guided tasks bearbeitet werden müssen, ob Fragebögen beantwortet werden müssen, ob neue Nachrichten vorhanden sind). zudem gab es links zu den Avataren, Geldwechsel, in-app messenger, guided-task review board…\n",
    "\n",
    "Additionally, an in-app alert was shown to the supervision officer about unanswered messages, critical events and time delay of a participant.\n",
    "\n",
    "#### The @myTabu intervention\n",
    "\n",
    "The content of the intervention arm focused exclusively on psychological meaningful risk factors<sup>[17](#ref-setoEmpiricallybasedDynamicRisk2023),[18](#ref-mannAssessingRiskSexual2010)</sup>. Already established therapeutic concepts from in-face community-based treatment programs for individuals who committed sexual offenses against children<sup>[41](#ref-brikenPraeventionSexuellenKindesmissbrauchs2017),[42](#ref-wildPreventionSexualChild2020)</sup> as well as cognitive-behavioral treatment concepts \\[see @tbl-sec-outcomes and @frombergerMyTabuAPlaceboControlled2021 for more details\\] have been adapted for be used online. Both programs have been designed for CSA as well as CSAM offenders. Parts relevant to the meaningful risk factors of both in-face programs have been digitalized and parts on risk factors not supported by empirical evidence have been skipped in order to shorten the HBI. Virtual participants (four male and one female with different offense histories \\[CSAM exclusive, CSA-exclusive, one released from high security hospital, one from prison and so on…..NOCH GENAU BESCHREIBEN\\]) accompanied the participant, narrate about their experiences, and make suggestions from the perspective of someone who is also affected (scored by professional actor). All modules within the intervention arm comprised techniques of motivational interviewing<sup>[43](#ref-rollnickMotivationalInterviewingTreatment2015)</sup> to enhance or maintain the motivation of the participants. The WBI is designed for female as well as male participants, but due to a lack of knowledge with regard to specific risk factors for female sex offenders at development of the HBI, the content remains identical for women and men. In order to make the HBI suitable for female participants, the used language was adapted and one female virtual participant has been designed and integrated.\n",
    "\n",
    "Since the treatment programs @myTabu is based on, are following slightly different theoretical frameworks, the intervention must be defined as an eclectic treatment approach. The intervention is based in cognitive-behavioral treatment techniques, follows the GLM and partly the RNR approach and integrates techniques from DBT and other thir wave psychotherapy.\n",
    "\n",
    "The placebo arm was developed to ensure the same mode, dose, and amount of support and attention by supporting online coaches as in the intervention arm - but the content of the modules was unrelated to meaningful dynamic risk factors. The content of the placebo condition comprised information on healthy living, e.g., healthy nutrition, physical activities, or healthy sleep. The amount of exercises was the same as in the experimental condition but exercises are specifically designed to not induce any sustainable effect. The entire content of the HBI is available online under an open-source license after publication (LINK will be provided after publication).\n",
    "\n",
    "During the clinical trial, in summary one male and three female online coaches cared the participants online. All coaches had a master degree in psychology, one coach ein approbierter Psychotherapeut. Regular meetings between online coaches and an experienced supervisor promoting treatment consistency and regular supervision (one meeting per month) took place. \\[MUSS DAS ZU DEN ERGEBNISSEN????\\]\n",
    "\n",
    "### Outcomes\n",
    "\n",
    "-   State the prespecified primary and secondary outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline), method of aggregation (eg, median, proportion), and timepoint for each outcome;\n",
    "\n",
    "#### Primary outcomes\n",
    "\n",
    "The study protocol predefined two primary endpoints. The first was the proportion of officially recorded re-offenses, considered the gold standard for evaluating the treatment efficacy of offender rehabilitation programs<sup>[44](#ref-beechCollaborativeOutcomeData2007)</sup>. This endpoint will be assessed five years after the last patient out (September 2030). The second primary endpoint, the Index of Desistance (IoD), was intended to measure the relative effectiveness of the intervention arm in reducing dynamic risk factors compared to the placebo arm. Originally, the IoD was conceptualized as a composite measure comprising three self-report instruments developed at the outset of the<sup>[**myTabu?**](#ref-myTabu)</sup> project: the Acute-SR, the Stable-SR, and the Checklist of Behavioral Misconduct (CMC)<sup>[45](#ref-nitscheErfassungAkutUnd2022)</sup>. However, the evaluation by<sup>[45](#ref-nitscheErfassungAkutUnd2022)</sup> revealed that the CMC exhibited low internal consistency (Cronbach’s α = 0.53). To improve psychometric quality, a comprehensive item reduction was undertaken. Based on these findings, and deviating from the Statistical Analysis Plan (SAP), the CMC was excluded from the primary outcome, and only the scales with reduced item sets were retained. Furthermore, we decided to report results for the validated CARES scale instead (see ??? for a detailed analysis of the IoD as defined in the SAP). Accordingly, the primary outcome is now defined as the Child Sexual Abuse Risk Evaluation Self-Report (CARES) scale, a composite instrument integrating the CARES-A, which assesses acute dynamic risk factors, and the CARES-S, which measures stable dynamic risk factors<sup>[46](#ref-sonjaetzlerDevelopmentInitialValidationsubmitted)</sup>. The CARES total score is calculated by summing the CARES-A and CARES-S total scores, producing a range from 0 to 102, with higher scores indicating greater severity of both acute and stable dynamic risk factors. The CARES-A scale evaluates seven acute dynamic risk factors associated with sexual reoffending in individuals convicted of at least one (contact or non-contact) sexual offense against children: (1) Preoccupation with Potential Victims, (2) Hostility, (3) Hypersexuality, (4) Rejection of Control Measures, (5) Emotional Crisis, (6) Loss of Social Support, and (7) Substance Use. Comprising 21 items, the CARES-A yields scores from 0 to 42; higher scores denote more pronounced acute dynamic risk. Reliability coefficients for the CARES-A range from α = .79 to α = .83. Analyses of social desirability revealed no significant correlations between CARES-A scores and either the Exaggeration of Positive Qualities or Negative Qualities<sup>[46](#ref-sonjaetzlerDevelopmentInitialValidationsubmitted)</sup>. The CARES-S scale assesses six stable dynamic predictors of sexual recidivism. It consists of 30 items covering: (1) Problematic Sexual Interests, (2) Problematic Emotion-Regulation, (3) Lack of Problem-Solving Skills, (4) Offense-Supportive Cognitions, and (5) Lack of Social Support. Five of these subscales correspond to empirically supported psychological risk factors for sexual recidivism<sup>[17](#ref-setoEmpiricallybasedDynamicRisk2023),[18](#ref-mannAssessingRiskSexual2010)</sup>. The CARES-S total score ranges from 0 to 60; higher scores indicate stronger stable dynamic risk factors. The reduced CARES-S achieved an internal consistency of α = .53. As with the CARES-A, no significant correlations with social desirability measures were found in the evaluation study<sup>[46](#ref-sonjaetzlerDevelopmentInitialValidationsubmitted)</sup>.Primary outcome data (CARES) were collected at seven measurement time points (see TABLE OF TIME POINTS).\n",
    "\n",
    "#### Secondary outcomes\n",
    "\n",
    "Pre–post difference scores of psychometric questionnaires in the treatment arm compared with the placebo arm are defined as secondary endpoints. All secondary endpoints, including their measurement variables, analysis metrics, aggregation methods, and time points, are summarized in \\[@tbl-sec-outcomes\\]. Each secondary endpoint corresponds to a questionnaire designed to assess (at least some aspects of) one of the risk factors targeted by the intervention modules. Each questionnaire is administered before (pre) and after (post) the module addressing the respective risk factor.<sup>[**apx-desc-sec-endpoints?**](#ref-apx-desc-sec-endpoints)</sup> provides a detailed description of each questionnaire."
   ],
   "id": "6adb5dab-41eb-478d-9c8a-404538bc01d3"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- {{< include _includes/tbl_sec_outcomes_riskfactors.qmd >}} -->"
   ],
   "id": "db01c17a-9178-47ab-8266-285fb0771975"
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Assessment of harms\n",
    "\n",
    "Stopping guidelines have been prospectively defined for the interim analysis. A participant was excluded if the responsible supervision officer or the online coach reports clear evidence for sexual recidivism or concrete preparations for any sexual recidivism. The clinical trial would have been stopped if an interim analysis at 12 months after first patient in (tested on subjects having completed at least two modules of the web-based intervention) demonstrates: (a) a significantly higher risk to re-offend (based on main outcome and number of reported significant events in the experimental condition compared to the placebo condition); (b) a significantly higher proportion of reported significant events (see a) in the experimental condition than in the placebo condition; (c) a significantly increased proportion of high-risk subjects (defined in terms of the main outcome) compared to the proportion at baseline.\n",
    "\n",
    "Re-offenses during working on the HBI as reported by the community supervisors were derived from the Exclusion Questionnaire (EQ). Furthermore, recidivism or concrete preparations for recidivism as reported in in-app messages or during working on a guided tasks have been measured in order to not oversee any potential risk. The EQ assess the reasons for exclusion in a structured manner and had to be filled in by the supervisor at exclusion of a participant. The EQ asks for XX potential reasons for exclusion, darin enthalten…. IThe EQ allows to specifiy multiple reasons for exclusion of a participant.\n",
    "\n",
    "> **Important**\n",
    ">\n",
    "> genauere Beschreibung des EQ und dessen Skalen\n",
    "\n",
    "Potential harms have been accessed by the Mood and Risk Questionnaire (MRQ). The MRQ was developed to assess acute changes with regard to emotional well-being (suicidal ideations, mental crisis) and thoughts associated with potential re-offenses. It consists of ten self-developed items, of which six are asking about thoughts and behaviors associated with potential re-offenses and four asking about the psychological and emotional state of the participant. The MRQ has been assessed before and after each session of the HBI. The MRQ slightly differs between the items in the pre and post measurements: all items of the pre measurement refer explicitly to the time between finishing last post measurement and before starting the new session (time not working on the HBI). The post measurement explicitly asks for the time during working on the session. The MRQ has not been mentioned in the SAP due to a mistake by the PI.\n",
    "\n",
    "Finally, detoriation of psychological well-being has been assessed with the WHO-5 Well-Being Index \\[WHO-5;<sup>[47](#ref-bechMeasuringDimensionPsychological2004)</sup>\\]. The WHO-5 is a self-report questionnaire that measures current mental well-being based on five items rated on a six-point Likert-scale ranging from 0 (at no time) to 5 (all of the time). The WHO-5 has shown good validity in measuring subjective well-being in clinical studies<sup>[48](#ref-toppWHO5WellbeingIndex2015)</sup>. The WHO-5 was administered before an after each session of the WBI. The WHO-5 has not been mentioned in the SAP due to a mistake by the PI.\n",
    "\n",
    "#### Ancillary outcomes\n",
    "\n",
    "Without predefined hypotheses, some questionnaires have been administered in an explorative manner. Since it has been discussed if a therapeutic alliance can be established even with offenders \\[LIT\\], it is important to proof if a therapeutic alliance was build during participation. The Working Alliance Inventory-Short Revised \\[WAI-SR;<sup>[49](#ref-horvathDevelopmentWorkingAlliance1986)</sup>;<sup>[50](#ref-horvathDevelopmentValidationWorking1989)</sup>\\] measures three dimensions of therapeutic alliance. For the purpose of this study, the original items of the German version<sup>[51](#ref-wilmersDeutschsprachigeVersionWorking2008)</sup> were adapted to be suitable for a web-based intervention. The items have to be rated on a five-point Likertscale ranging from 1 (never) to 5 (always). It was adapted to suit to the online-coach as well as the supervision-officer resulting in 16 items. Internal consistency (Cronbach’s α) of the original questionnaire ranges from 0.82 to 0.90<sup>[51](#ref-wilmersDeutschsprachigeVersionWorking2008)</sup>. The WAI-SR was developed in a version asking for bonding with the supervisor as well as a version asking for therapeutic alliance with the online coach. The WAI-SR was assessed only on six timepoints, always after finishing the first session of a module.\n",
    "\n",
    "In order to assess a possible volunteer-effect, the Questionnaire of Non-Participation (QNP) was developed to assess possible reasons for not taking part in the clinical trial and to assess the baseline characteristics of non-participanmts in order to be able to get a representative baseline for all individuals convicted for CSA or CSAM under community supervision in Germany. Up to now, there exists no official statistic on individuals under community supervision at Germany. The QNP was only administered if a potential participant will not take part in the study but has given informed consent to fill out the QNP.\n",
    "\n",
    "Finally, the Questionnaire for Acceptance of Technology (ATQ) was administered in order to assess acceptance of technology and its predictors within the framework of this project. Further, the Questionnaire of Subjective Therapy Preconditions \\[SBV-R;<sup>[52](#ref-endresFragebogenSubjektivenBehandlungsvoraussetzungen2010)</sup>\\] was used to measures the subscale “pressure of pain” of the multidimensional construct of therapy and treatment preconditions in offenders. These questionnaires were parts of dissertation projects and preliminary data from the intermediate analysis has already been published with regard to the ATQ<sup>[53](#ref-schroderAcceptanceWebBasedIntervention2024),[54](#ref-schroderEngagementWebbasedIntervention2025)</sup> or will be published elsewhere.\n",
    "\n",
    "### Sample size\n",
    "\n",
    "A rate of 50% of screened participants taking voluntarily part in the clinical trial is assumed. Based on the estimation responsible minsitries, it was expected to see 1,165 subjects eligible for participation during the recruitment period of which 50% (n = 582) have been expected to participate in the study. Taking a dropout of 26.4% (128) into account, it was expected to see n = 428 subjects completing HBI. With n = 214 subjects in both conditions (treatment and placebo) it is possible to detect small effects (d = 0.27) with a power of 80% at a significance level α = 5%.\n",
    "\n",
    "### Statistical analysis\n",
    "\n",
    "Data analysis was performed using the software R, version 4.5.0<sup>[55](#ref-rcoreteamLanguageEnvironmentStatistical2025)</sup>. Interim analysis has been done by the data safety monitoring board (DSMB) on April 20, 2022. After receiving permission by the DSMB, partial data from the interim analysis (n = ???; only baseline measures; no data of primary or secondary endpoints) have been already published<sup>[53](#ref-schroderAcceptanceWebBasedIntervention2024),[54](#ref-schroderEngagementWebbasedIntervention2025)</sup>. For all analyses on the primary and safety endpoints the intention-to-treat (ITT) population will be used. The ITT population consists of all participants who have completed at least one module but not necessarily answered the questionnaires ate the end of module one.\n",
    "\n",
    "The primary outcome (CARES total score) was analyzed by means of Gaussian linear model for repeated measures (MMRM) with treatment group, time (six time-points; after each online intervention module), treatment-by-time interaction, and the randomization strata as factors (offense type, type of CS, external treatment in addition to CSaU), baseline measurements (at clearing up) of the outcome and potentially time span from baseline as covariate and the classical IoD as dependent variable. The error terms were assumed to follow a multivariate normal distribution with unstructured covariance. Least squares mean changes from baseline are reported for the treatment groups with 95% confidence interval (CI) as well as the difference between the least squares treatment group means with 95% CI and p-value testing the null hypothesis of no treatment effect. A sensitivity analysis on imputed values complemented the analysis. Imputation has been done using multiple reference based imputation followed by ANCOVA models<sup>[56](#ref-wolbersStandardReferencebasedConditional2022)</sup>. Additionally, differences (post - pre) of IoD total score have been compared between the treatment groups using the Brunner-Munzel test for unpaired data<sup>[57](#ref-brunnerNonparametricBehrensFisherProblem2000)</sup>. All patients who discontinue from the study are identified and the extent of their participation in the study reported. If discontinuation from study is due to clear evidence for recidivism or concrete preparation for or intention to recidivism (assessed by responsible supervision officer or online coach) the subject receives the maximal value for IoD for the remaining measurements (assuming the worst case of a failed treatment). In all other cases of drop-out, the reason is recorded.\n",
    "\n",
    "To analyze the treatment effects of each individual module, secondary endpoints have been analyzed using the non-parametric Brunner-Munzel test<sup>[57](#ref-brunnerNonparametricBehrensFisherProblem2000)</sup> for paired data comparing the pre- and post-module scores and adjusting the p-values using the Bonferroni-Holm’s method to control the family-wise error rate. The effect of each module on the scores corresponding to the secondary endpoints was exploratory further analyzed by fitting linear models with treatment group and the randomization strata as factors (offense type, type of CS, external treatment in addition to CSaU), pre module scores as covariate and post module scores as dependent variable if appropriate. If necessary, the scores have been transformed before the analysis. If the assumptions of a linear model were not fulfilled either an ordinal regression model was fitted analogously instead or the score was dichotomized in order to fit a logistic regression model analogously. Analyses on the secondary endpoints were carried out on the specific per-protocol (PP) population. The PP population for a specific module consists of all participants who have completed this module.\n",
    "\n",
    "Proportions of occurrences of re-offences during the clinical trial (as assessed by the EQ) were estimated with 95% confidence intervals for both groups using the beta product confidence procedure for right censored data<sup>[58](#ref-fayPointwiseConfidenceIntervals2013)</sup> and differences in the proportions between both groups are estimated with 95% confidence intervals using the beta product confidence procedure for right censored data<sup>[59](#ref-fayCombiningOneSampleConfidence2015)</sup>. Kaplan–Meier survival curves were estimated to examine time to first recidivism event as reported by supervision officers. In order to assess the frequency of clinical significant detoriations in psychological well-being, a detoriation of more than 10 points on the WHO-5 score between the beginning and end of a module was defined as a clinical significant detoriation<sup>[48](#ref-toppWHO5WellbeingIndex2015)</sup>. Frequencies and percentages of the number of clinically significant detoriations of psychological well-being (WHO-5 score) as well as frequencies and percentages of the scores on the singe-item subscales of the MRQ were provided for each treatment arm by session and differences between arms on each subscale were compared using Fisher’s exact test. Only measures of the MRQ after each session are considered since the MRQ pre questionnaires asked explicitly on the time before the session (see Table XX - XY for results on the MRQ pre-scores).\n",
    "\n",
    "Ancilliary outcomes have been analyzed in a exporatory manner. In order to analyze the effect of the treatment arm on psychological well-being, the total score of the WHO-5 was analyzed by means of Gaussian linear model for repeated measures (MMRM) with treatment group, time (six time-points; after each online intervention module), treatment-by-time interaction, and the randomization strata as factors (offense type, type of CS, external treatment in addition to CSaU), baseline measurements (at clearing up) of the outcome and potentially time span from baseline as covariate and the classical IoD as dependent variable. The error terms were assumed to follow a multivariate normal distribution with unstructured covariance. Least squares mean changes from baseline are reported for the treatment groups with 95% confidence interval (CI) as well as the difference between the least squares treatment group means with 95% CI and p-value testing the null hypothesis of no treatment effect. The same analysis rationale was applied for the WAI-SR.\n",
    "\n",
    "### Role of funding source\n",
    "\n",
    "The work was funded by the German Federal Ministry of Education and Research (Funding number: 01KR1807A). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report."
   ],
   "id": "79047aa4-cfc2-4af1-84ee-0def4d558bac"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- RESULTS SECTION -->"
   ],
   "id": "8bd7caae-b1ef-42fc-8413-5bd8a85c391d"
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Results\n",
    "\n",
    "Between March 01, 2020, and Septembre 30, 2024, n = 385 individulas who committed sexual offenses against children have been screened for eligibility, of whom 16 have not been randomized. The trial was closed at Septembre 30, 2024 before all participants have been able to finish the web-based intervention due to a lack of further funding. N = 369 individuals were randomly assigned, n = 182 to the placebo arm and n = 187 to the intervention arm. One individual was misallocated to the intervention arm instead to the placebo and has been excluded from analysis. N = 213 participants have been included in the ITT sample (n = 107 in the intervention arm and n = 106 in the placebo arm). \\[@fig-consort-flowchart-detailed\\] shows the CONSORT flowchart with detailed information on the number of and reasons for dropouts for each module. Overall, n = 99 finished the web-based program, n = 44 (30.20%) in the intervention arm and n = 55 (22.40%) in the placebo arm. Only two female participants were randomized, of whom one enters the ITT sample. All participants (n = 213 \\[100%\\]) in the itt sample had the German nationality. Due to technical reasons, six participants of the ITT sample (n = 3 \\[0.03%\\] in the intervention arm, n = 3 \\[0.03%\\] in the placebo arm) data points of one measurement time point are missing."
   ],
   "id": "07263d74-4b36-4b3f-9766-769092c8bd66"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- {{< include _includes/fig_flowchart_detailed.qmd >}} -->"
   ],
   "id": "b44595f4-c837-48e5-bfb9-cf88154b412c"
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Follow-up\n",
    "\n",
    "Overall, n = 124 participants dropped out until the end of the trial. Dropout-reasons as reported by the supervision officers for the randomized sample are summarized in Table @tbl-exclusion-reasons-itt for the ITT sample. Additionally, one participant has to be excluded by the prinicpal investigator due to unwillingness to work seriously on the guided tasks as well as unacceptable language in in-app messages. With the exception of this one participant, all participants had be excluded by their responsible community supervisor."
   ],
   "id": "31c878ad-85ee-471e-84fa-d2117869b2f1"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- {{< include _includes/tbl_exclusion_reasons_itt.qmd >}} -->"
   ],
   "id": "b315c214-a1ae-4fff-a7c5-cc44ad9718ee"
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Protocol deviations\n",
    "\n",
    "Participants of both trial arms have been advised to work on each session within seven days, on each module within 28 days and ti finish the HBI within 196 days. \\[@fig-time-to-finish-module-itt-boxplot\\] demonstrates that the time, participants needed for finishing the consecutive modules of the HBI, differs from the advised time, in some modules in a statistically significant manner. \\[@tbl-deviance-from-advised-time-frequency\\] shows the frequency of protocol deviations and results of fisher’s exact tests with regard to advised HBI time.\n",
    "\n",
    "> **Important**\n",
    ">\n",
    "> \\[Müsste man hier nicht ein Generalised Linear Mixed Models (GLMM) rechnen, anstatt dieser ganzen pariwise comparisons????\\]\n",
    "\n",
    "In the Fisher’s exact tests, three module comparisons showed statistically significant differences between the intervention and placebo arm based on unadjusted p‑values. For Module 3, participants in the intervention arm more often needs more time to finish a moduel than advised (n = 68, 99%) compared to the placebo arm (n = 67, 89%), while the As advised category occurred exclusively in the placebo group (n = 6, 8.0% vs. n = 0, 0%). This difference was statistically significant before adjustment (Cramér’s V = 0.210; p = 0.029), but did not remain significant after Holm‑Bonferroni adjustment (q = 0.12). For Module 4, the durations as advised were observed less frequently in the intervention group (n = 1, 1.6%) compared to the placebo group (n = 10, 15%), whereas longer durations remained the dominant in both groups (n = 57, 93% vs. n = 55, 81%). This difference reached statistical significance before adjustment (Cramér’s V = 0.230; p = 0.024), but fell short of significance after correction for multiple testing (q = 0.12). For Module 5, the shorter times were reported more often in the intervention group (n = 4, 8.0%) compared to none in the placebo group, with longer times being the most frequent outcome in both groups (n = 45, 90% vs. n = 48, 87%). The difference was significant before adjustment (Cramér’s V = 0.280; p = 0.013) and showed a trend after adjustment (q = 0.078), not meeting the predefined threshold of 0.05. All other modules have not reached statistical significance (all p ≥ 0.075), but showed a comparable figure with longer times as advised with the highest frequency and low ferquency of participants finished the module in the advised time. In consequence, time to finish modules has been considered as covariable in the MMRMs for the primary endpoints in an exploratively manner.\n",
    "\n",
    "Interestingly, the reasons for these protocol deviations seems not to be\n",
    "\n",
    "> **Important**\n",
    ">\n",
    "> \\[FEHLT: Unterschiede zwischen den Gruppen in der Bearbeitungsdauer?\\]\n",
    "\n",
    "### Baseline characteristics\n",
    "\n",
    "\\[@tbl-baseline-characteristics\\] shows an overview of various sociodemographic, criminological and mental health baseline characteristics. With regard to strata \\[see Table XXXX\\], only n = 89 (40%) participants of the ITT sample were mixed offenders (at least one conviction §176 ff StGB; n = 44 \\[41%\\] in the intervention arm and n = 45 \\[40%\\] in the placebo arm) and n = 132 (60%) were hands-off offenders (only convictions based on \\$184b StGB; n = 64 \\[59%\\] in the intervention arm and n = 68 \\[60%\\] in the placebo arm). The majority of participants (n = 176 \\[80%\\]) were under community supervision (Bewährungshilfe §§56, 57 StGB; n = 88 \\[81%\\] in the intervention arm and n = 88 \\[78%\\] in the placebo arm). Only n = 45 (20%) have been under post-release supervision (Führungsaufsicht §§68 ff StGB; n = 20 \\[19%\\] in the intervention arm and n = 25 \\[22%\\] in the placebo arm). N = 70 (32%) of the ITT sample had additional external treatment in addition to community supervision as usual (n = 33 \\[31%\\] in the intervention arm and n = 37 \\[33%\\] in the placebo arm), n = 151 (68%) had no additional treatment (n = 75 \\[69%\\] in the intervention arm and n = 76 \\[67%\\] in the placebo arm). The majority of participants (n = 180 \\[81%\\]) had a low static risk to re-offend at baseline (n = 87 \\[81%\\] in the intervention arm and n = 93 \\[82%\\] in the placebo arm). N = 41 (19%) had a low-medium, medium-high or high risk to re-offend (n = 21 \\[19%\\] in the intervention arm and n = 20 \\[18%\\] in the placebo arm)."
   ],
   "id": "b0811219-cd2c-4943-b274-f21fa796259b"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- {{< include _includes/tbl_baseline_characteristics.qmd >}} -->"
   ],
   "id": "592ed9e8-df57-4844-9392-3171854585d7"
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Overall, n = 70 (32%) of the ITT sample received an external (f2f) treatment during participation (psychotherapy and/or medical treatment), but the court ordered this for n = 124 (56%). Only n = 48 (38.71%) of all participants who have an ordered treatment also in fact received external treatment at enrolement, the majority (n = 76; 61.29%) not.\n",
    "\n",
    "> **Important**\n",
    ">\n",
    "> \\[FEHLT: ICD-11 screener, PHQ-D, \\]\n",
    ">\n",
    "> PHQ-D\n",
    ">\n",
    "> diagnosis (based on Supervisors oder ???)\n",
    "\n",
    "### Main outcome\n",
    "\n",
    "The mixed model for repeated measurements (MMRM) for the CARES total score showed no significant group differences for the interaction term timepoint × treatment (all p‑values ≥ 0.149; see \\[@tbl-prim-cares-mmrm\\]). The β estimates for the intervention group compared to the placebo group were 0.11 at module one, −1.20 at module two, −0.30 at module three, −0.39 at module four, 0.62 at module five, and 0.02 at module six. The factor Additional treatment showed a trend-level effect, with participants receiving additional treatment having lower scores (β = −1.10; p = 0.096). Similarly, Conviction revealed a trend, indicating that participants with only §184b StGB convictions (“hands-off”) had lower CARES total scores compared to those with at least one conviction under §§176 ff StGB (“hands-on”) (β = −1.20; p = 0.076). A strong and highly significant positive association was found for baseline scores, (β = 0.87; p \\< 0.001). Static recidivism risk (baseline) showed a non-significant positive association (β = 0.45; p = 0.108), and no significant effect was observed for Type of supervision (β = 0.57; p = 0.499). Regarding timepoint, a significant increase was observed at module two compared to module one (β = 0.99; p = 0.047), while all other modules showed no significant differences. Also, the explorative MMRM for the CARES total score with the additional covariate time since start of module 1 showed no significant group differences for the interaction term timepoint × treatment (all p‑values ≥ 0.293; see \\[@tbl-iod-reduced-mmrm-explorative-time-since-first-module\\]) as well as the explorative MMRM with the additional covariate time since recruitment (all p‑values ≥ 0.284; see \\[@tbl-iod-reduced-mmrm-explorative-time-since-recruitment\\])."
   ],
   "id": "4e4607fc-1127-4014-9873-c43af58b9762"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- {{< include _includes/tbl_prim_cares_mmrm.qmd >}} -->"
   ],
   "id": "39a0d76b-66eb-4796-b2f5-b1f0775c2e1e"
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Explorative pairwise comparisons of the difference from baseline scores between treatment arms revealed a statistical trend at module two (p = 0.051; p adj. = 0.31). The difference from baseline was lower in the intervention arm (M = -0.3 ± 3.9 SD) than in the placebo arm (M = 1.0 ± 5.5 SD). All other comparisons showed none significant results (all p-values ≥ 0.53; see \\[@tbl-prim-cares-diffscore\\]). Exploratory pre–post comparisons of the CARES total score within the intervention arm showed a significant decrease for module one (t = -2.85, p = 0.0050; Holm–Bonferroni q = 0.030; estimated relative effect p̂ = 0.451, 95% CI \\[0.417, 0.485\\]). The mean total score decreased from 14 ± 8 SD pre to 12 ± 9 SD post. All other modules showed no statistically significant changes (all p-values ≥ 0.15 see @tbl-prim-cares-pre-post-pairwise-intervention). Exploratory pre–post comparisons within the placebo arm showed a significant decrease for module one (t = -3.88, p \\< 0.0001; Holm–Bonferroni q \\< 0.0001; estimated relative effect p̂ = 0.428, 95% CI \\[0.392, 0.465\\]). The mean score decreased from 12 ± 8 SD pre to 11 ± 9 SD post. Two modules showed nominal pre–post differences that did not survive multiplicity adjustment: Supervision and social relationships (p = 0.050, q = 0.24) suggesting a slight increase, and Emotion management (p = 0.047, q = 0.24) suggesting a decrease. All other modules showed no statistically significant changes (all p ≥ 0.54; see \\[@tbl-prim-cares-pre-post-pairwise-placebo\\]).\n",
    "\n",
    "Explorative analysis of the primary endpoint, as initially defined in the SAP, reveals no divergent results: the MMRM shows no significant group differences for the interaction term timepoint × treatment (all p‑values ≥ 0.588; see \\[@tbl-prim-mmrm\\]).\n",
    "\n",
    "### Secondary outcomes\n",
    "\n",
    "\\[@tbl-sec-pairwise-intervention\\] shows descriptive statistics and the results of the pairwise comparisons for each secondary endpoint for the intervention arm. In the intervention arm, three measures demonstrated statistically significant pre–post differences. The CVTRQ total score increased from 84 ± 7 SD at pre-measurement to 86 ± 8 SD at post-measurement (p = 0.0060, q = 0.078), indicating improved treatment readiness. The DERS impulsivity subscale score rose from M = 6.24 ± 2.26 SD to M = 6.72 ± 2.25 SD (p = 0.0050, q = 0.070), suggesting an increase in impulsivity-related difficulties. In contrast, the ESIQ total score decreased from M = 90 ± 12 SD to M = 87 ± 12 SD (p = 0.0010, q = 0.015), reflecting a reduction in explicit sexual interests. One measure reached nominal significance but did not survive adjustment: the SSIC score increased slightly from M = 26.5 ± 4.6 SD to M = 27.1 ± 4.3 SD (p = 0.049, q = 0.59), indicating a possible, though not statistically robust, enhancement in perceived self-efficacy. The SOI-R subscale score decreased from M = 11 ± 20 SD to M = 9 ± 21 SD (p = 0.071, q = 0.79), suggesting a potential reduction in the desire for sexual activity with children, although this change did not reach statistical significance after adjustment. Several additional measures showed statistical trends. The UCLA total score decreased from M = 28.5 ± 3.9 SD to M = 28.0 ± 4.1 SD (p = 0.066, q = 0.73), suggesting a possible reduction in loneliness levels. The OQMPR score decreased from M = 29 ± 9 SD to M = 28 ± 9 SD (p = 0.084, q = 0.84), indicating a potential reduction in psychological reactance. All other measures, including RCQ, F-Soz-U, BIS-15, CUSI, NARQ (externalizing strategies), SPSI-R, BMS, EKK-R, and HBI-19, did not show significant pre–post differences (all p-value ≥ 0.13)."
   ],
   "id": "2fd70caf-bb3a-4483-8ca7-0dc3c891234b"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- {{< include _includes/tbl_sec_pairwise_intervention.qmd >}} -->"
   ],
   "id": "963760a6-322d-4532-8950-d8cace233d90"
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "\\[@tbl-sec-pairwise-placebo\\] shows descriptive statistics and the results of the pairwise comparisons for each secondary endpoint for the placebo arm. In the placebo arm, only one measure demonstrated a statistically significant pre–post difference. The F-Soz-U total score increased from M = 3.74 ± 0.84 SD at pre-measurement to M = 3.88 ± 0.89 SD at post-measurement (p = 0.0030, q = 0.045), indicating improved perceived social support. No additional measures reached nominal significance (p \\< 0.05 without adjustment), and no outcomes showed statistical trends. All other measures, including CVTRQ, RCQ, OQMPR, UCLA, BIS-15, CUSI, DERS impulsivity, NARQ externalizing strategies, SPSI-R, BMS, ESIQ, SOI-R, SSIC, EKK-R, and HBI-19, did not show significant pre–post differences (all p-values ≥ 0.12)."
   ],
   "id": "57bbf4b2-3787-46fc-a7db-1792beaf74f9"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- {{< include _includes/tbl_sec_pairwise_placebo.qmd >}} -->"
   ],
   "id": "94226e56-d451-4d12-a67d-6161fa988e2c"
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Exploratory subscale analysis of the CVTRQ demonstrated only on the subscale Attitudes and Motivation a significant difference in the intervention arm (p \\< 0.0001, q \\< 0.0001) with lower values before module one (M = 26.29 ± 3.01 SD) than after module one (M = 27.19 ± 2.83 SD). All other subscales showed no significant difference or statistically trend in the intervention arm (all p 0.11; see \\[@tbl-sec-cvtrq-subscores-pairwise-intervention\\]). Further exploratory subscale analysis within the intervention arm for the ESIQ showed a significant difference before (M = 47 ± 9 SD) and after module six (M = 44 ± 8 SD) on the subscale Fantasy (p \\> 0.0001, q \\< 0.0001). For the subscale Behavior there was a statistical trend with in the intervention arm (p = 0.065, q = 0.065; see \\[@tbl-sec-esiq-subscores-pairwise-intervention\\]).\n",
    "\n",
    "Exploratory analysis of differences from baseline of secondary endpoints revealed two questionnaires demonstrating statistically significant differences between the placebo and intervention arms (see \\[@tbl-prim-cares-diffscore\\]). The ESIQ total score decreased in the intervention group (M = –3.6 ± 5.4 SD), while remaining essentially unchanged in the placebo arm (M = –0.1 ± 7.9 SD; p = 0.0020, q = 0.030), reflecting a statistically significant reduction in explicit sexual interests only in the intervention group. The difference from baseline of the DERS impulsivity subscale was higher in the intervention group (M = 0.49 ± 2.10 SD) compared to the placebo arm (M = –0.15 ± 1.24 SD; p = 0.024, q = 0.34), indicating a nominal, but not statistically robust, increase in impulsivity-related difficulties in the intervention group and decrease in the placebo group during module three. One additional questionnaire showed a statistical trend: the SSIC difference from baseline score was slightly higher in the intervention arm (M = 0.6 ± 3.6 SD) compared to the placebo arm (M = 0.1 ± 4.5 SD; p = 0.077, q \\> 0.99), suggesting a potential, though not statistically supported, improvement in perceived self-efficacy in reducing sexual interest on children. All other measures, including CVTRQ, RCQ, F-Soz-U, OQMPR, UCLA, BIS-15, CUSI, NARQ (externalizing strategies), SPSI-R, BMS, EKK-R, SOI-R, and HBI-19, showed no meaningful differences between groups (all p-values ≥ 0.14, see \\[@tbl-prim-cares-diffscore\\]).\n",
    "\n",
    "### Harms\n",
    "\n",
    "The interim analysis provided no evidence for the necessity to stopp the trial. During the clinical trial, wether supervision officer nor online coaches reported hints to recidivism or concrete preparation for recidivism in in-app messages or during working on a guided tasks. Kaplan–Meier survival curves for time to first recidivism event (as reported by supervision officers in the EQ) indicated a very low incidence of recidivism in both study arms during the first year after initiation of module 1 \\[see @fig-kaplan-meyer-recidivism\\]. After 12 months, the estimated proportion of participants without recidivism was 1.00 (95% CI \\[0.94, 1.00\\]) in the intervention group (n = 108) and 0.98 (95% CI \\[0.88, 1.00\\]) in the placebo group (n = 113). Two recidivism events were observed in the placebo group, whereas no events occurred in the intervention group. A substantial proportion of participants were censored prior to the 12-month follow-up (47% in the intervention group, 66% in the placebo group; see \\[@tbl-difference-proportion\\]). The between-group comparison of the proportions without recidivism at one year (placebo minus intervention arm) yielded a difference of –0.022 (95% CI \\[–0.12, 0.046\\]; p = .76), indicating no statistically significant effect of the intervention compared to placebo (see \\[@tbl-proportion-without-recidivism\\]).\n",
    "\n",
    "\\[@tbl-who-adverse-events\\] summarises the rates, effect sizes, and statistical outcomes for clinically significant deterioration in mental well-being across intervention modules. Event rates ranged from 12% to 29% in the intervention arm and 11% to 24% in the placebo arm, with effect sizes of Cramér’s V  between V = 0.010 and V = 0.230. Only module four demonstrated nominal statistical significance prior to multiple‑testing correction: 29% (18/62) of intervention participants versus 11% (8/72) of placebo participants experienced the event (Cramér’s V = 0.230, Fisher’s exact p = 0.015). This association did not remain significant after adjustment for multiple comparisons (q = 0.089). All other module comparisons showed non‑significant differences (all all p-values ≥ 0.47 with all effect sizes ≤ 0.0709). Event proportions in these modules had overlapping 95 % confidence intervals between arms, indicating no evidence for differential risk.\n",
    "\n",
    "> **Important**\n",
    ">\n",
    "> Fehlt: Mood and Risk Questionnaire (MRQ)\n",
    "\n",
    "### Ancillary outcomes\n",
    "\n",
    "The mixed model for repeated measurements (MMRM) for the WHO‑5 total score showed no significant group differences for the interaction term timepoint × treatment (all p‑values ≥ 0.11; see \\[@tbl-prim-who-mmrm\\]). The β estimates for the intervention group compared to the placebo group were 1.7 at module one (post), −1.8 at module two (before), −1.6 at module two (post), −0.86 at module three (before), −4.5 at module three (post), 0.10 at module four (before), −4.3 at module four (post), −2.4 at module five (before), −2.9 at module five (post), −1.9 at module six (before), and −0.15 at module six (post). The factor Additional treatment showed no significant effect (β = 0.25; p = 0.91), and Type of supervision similarly revealed no significant association (β = −2.9; p = 0.29). No significant effect was observed for Offense type (hands-on vs. hands-off) (β = 1.9; p = 0.40). Static recidivism risk (baseline) showed a non‑significant negative association (β = −0.94; p = 0.30). A strong and highly significant positive association was found for baseline WHO‑5 scores (β = 0.68; p \\< 0.0001). Regarding timepoint, none of the modules showed significant differences compared to module one (post; all p‑values ≥ 0.24).\n",
    "\n",
    "Only XX participants provided the QNP, thus no results can be reported.\n",
    "\n",
    "Unfortunately, only n = ??? \\[STIMMT NICHT!\\] of potential participants has given informed consent to fill out the QNP. In consequence, we did not analyse this questionnaire.\n",
    "\n",
    "> **Important**\n",
    ">\n",
    "> \\[FEHLT: QNP\\]\n",
    "\n",
    "The mixed model for repeated measurements (MMRM) for the WAI‑SR total score (coach) showed significant group differences for several timepoint × treatment interaction terms (see \\[@tbl-anc-wai-coach-mmrm\\]). The β estimates for the intervention group compared to the placebo group were 2.4 at module two (post; p = 0.025), 3.8 at module three (post; p = 0.0044), 3.4 at module four (post; p = 0.0067), 2.1 at module five (post; p = 0.13), and 4.3 at module six (post; p = 0.0051). The factor Additional treatment showed no significant effect (β = 1.1; p = 0.34), and Type of supervision similarly revealed no significant association (β = 1.2; p = 0.39). No significant effect was observed for Offense type (hands‑on vs. hands‑off) (β = −1.2; p = 0.31). Static recidivism risk (baseline) showed a non‑significant negative association (β = −0.59; p = 0.22). A strong and highly significant positive association was found for baseline WAI‑SR scores (β = 0.67; p \\< 0.0001). Regarding timepoint, none of the modules showed significant differences compared to module two (post; all p‑values ≥ 0.15). Pairwise pre–post comparisons for the WAI‑SR total score (coach) revealed statistically significant increases within the intervention arm at module two (post; M = 42 ± 11 SD to M = 44 ± 9 SD; p = 0.0020, q = 0.010) and module six (post; M = 46 ± 11 SD to M = 49 ± 9 SD; p = 0.0040, q = 0.016). These findings indicate an improvement in the therapeutic alliance as perceived by the coach at these timepoints. No other modules in the intervention group showed statistically significant pre–post changes (all q-values ≥ 0.62). In contrast, the placebo arm demonstrated no statistically significant pre–post changes in WAI‑SR scores for any module (all q-values \\> 0.99; see \\[@tbl-anc-wai-coach-pre-post-pairwise-intervention\\] and \\[@tbl-anc-wai-coach-pre-post-pairwise-placebo\\]). \\[Diskussion: This pattern of results supports the significant timepoint × treatment interaction effects detected in the MMRM analysis, showing that improvements in the coach-rated working alliance occurred selectively in the intervention group during module two and module six.\\] Exploratory analysis of difference scores for the WAI‑SR total score (coach) between treatment groups revealed two timepoints with nominal or trend-level differences (see \\[@tbl-anc-wai-coach-diffscore\\]). The change from module one (pre) to module two (post) was higher in the intervention arm (median = 3 \\[Q1 = −2, Q3 = 8\\]) compared to the placebo arm (median = 1 \\[Q1 = −3, Q3 = 5\\]; p = 0.025, q = 0.13), suggesting a possible early improvement in the coach-rated working alliance in the intervention group, though this effect did not survive adjustment. A further difference score — from module five (post) to module six (post) — was likewise higher in the intervention group (median = 2 \\[Q1 = 0, Q3 = 6\\]) compared to the placebo group (median = 0 \\[Q1 = −2, Q3 = 4\\]; p = 0.036, q = 0.14), indicating a potential late-stage improvement, also not statistically robust after adjustment. All other difference scores (modules two to four) showed no meaningful group differences (all q-values ≥ 0.18). This pattern aligns with the MMRM and pairwise comparison findings, indicating that notable gains in coach-rated working alliance tended to occur in the intervention group at early and late stages of the program, without reaching statistical significance after multiple-comparison correction.\n",
    "\n",
    "The mixed model for repeated measurements (MMRM) for the WAI‑SR total score (supervisor) showed significant group differences for several timepoint × treatment interaction terms (see \\[@tbl-prim-wai-supervisor-mmrm\\]). The β estimates for the intervention group compared to the placebo group were 2.3 at module two (post; p = 0.0073), 3.0 at module three (post; p = 0.0061), 3.2 at module four (post; p = 0.0022), 2.1 at module five (post; p = 0.068), and 3.6 at module six (post; p = 0.0038). The factor Additional treatment showed no significant effect (β = 1.0; p = 0.26), and Type of supervision similarly revealed no significant association (β = 1.6; p = 0.15). No significant effect was observed for Offense type (hands‑on vs. hands‑off) (β = −1.2; p = 0.20). Static recidivism risk (baseline) showed a non‑significant negative association (β = −0.66; p = 0.086). A strong and highly significant positive association was found for baseline WAI‑SR scores (β = 0.70; p \\< 0.0001). Regarding timepoint, none of the modules showed significant differences compared to module two (post; all p‑values ≥ 0.059). Pairwise pre–post comparisons for the WAI‑SR total score (supervisor) revealed a statistically significant increase within the intervention arm at module two (post; M = 43 ± 9 SD to M = 46 ± 8 SD; p \\< 0.0001, q \\< 0.0001). A smaller, nominally significant increase was also observed at module six (post; M = 49 ± 9 SD to M = 50 ± 8 SD; p = 0.046, q = 0.18), which did not survive adjustment for multiple comparisons. No other modules in the intervention group showed statistically significant pre–post changes (all q-values ≥ 0.35). In contrast, the placebo arm demonstrated no statistically significant pre–post changes in WAI‑SR scores for any module (all q-values \\> 0.99; see \\[@tbl-anc-wai-sv-pre-post-pairwise-intervention\\] and \\[@tbl-anc-wai-sv-pre-post-pairwise-placebo\\]). This pattern of results is consistent with the significant timepoint × treatment interaction effects detected in the MMRM analysis, indicating that improvements in the supervisor-rated working alliance occurred selectively in the intervention group, particularly at module two, with a smaller, non‑robust change at module six. Exploratory analysis of difference scores for the WAI‑SR total score (supervisor) between treatment groups revealed one statistically significant effect (see \\[@tbl-anc-wai-sv-diffscore\\]). The change from module one (pre) to module two (post) was higher in the intervention arm (median = 4 \\[Q1 = −1, Q3 = 6\\]) compared to the placebo arm (median = 1 \\[Q1 = −3, Q3 = 4\\]; p = 0.0090, q = 0.045), indicating a greater early improvement in the supervisor‑rated working alliance among participants receiving the intervention. A further difference score — from module five (post) to module six (post) — showed a statistical trend, with higher scores in the intervention group (median = 1 \\[Q1 = 0, Q3 = 4\\]) compared to the placebo group (median = 0 \\[Q1 = −2, Q3 = 2\\]; p = 0.061, q = 0.24), suggesting a potential late‑stage improvement, although this effect did not survive adjustment. All other difference scores (modules two to five) showed no meaningful group differences (all q-values ≥ 0.40). This pattern is consistent with the MMRM and pairwise comparison results, underscoring that notable improvements in supervisor‑rated working alliance were observed primarily in the intervention arm at module two, with a possible but non‑robust gain at module six."
   ],
   "id": "c3c88a41-a66a-4606-8ab6-762a99a5d21b"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- DISCUSSION SECTION -->"
   ],
   "id": "f9ee57e1-7373-40a3-8262-d8b9a8635cc3"
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Discussion\n",
    "\n",
    "In this worldwide first randomized placebo-controlled clincial trial of a HBI for individuals who committed sexual offenses against children (tertiary prevention), in contrast to our hypothesis, no significant reduction of risk factors in the intervention arm compared to the placebo arm has been observed on the primary endpoint. The MMRM for the CARES showed no significant timepoint × treatment interaction effects. Among secondary endpoints, several risk factors showed significant pre–post changes within the intervention arm in line with our hyptheses — most notably, increases in treatment readiness (CVTRQ), decreases in explicit sexual interests (ESIQ), and increases in impulsivity-related difficulties (DERS impulsivity) — while the placebo arm showed an isolated improvement in perceived social support (F‑Soz‑U). Between-group difference scores confirmed a significant reduction in explicit sexual interests in the intervention group, with all other questionnaires yielding non‑significant or non‑robust results. Ancillary analyses demonstrated consistent, statistically robust improvements in working alliance ratings (WAI‑SR) for both coaches and supervisors in the intervention group, particularly after module 1 and, to a lesser extent, after module five. No comparable changes occurred in the placebo arm. Importingly, no evidence emerged for an increased risk of recidivism or clinically significant deterioration in mental well-being attributable to the intervention; event rates for both were low and similar between arms. Taken together, the HBI did not lead to measurable changes in the primary CARES outcome but was associated with selected improvements in psychological meaningful risk factors — most notably reduced sexual interest in children and strengthened working alliance with coaches and supervisors — without indications of harm also for low-risk individuals.\n",
    "\n",
    "The trial follows the principles of the Collaborative Outcome Data Committee (CODC) guidelines for evaluation of sexual offender treatments<sup>[44](#ref-beechCollaborativeOutcomeData2007)</sup> as well as the CONSORT guidelines for randomized trials \\[see @tbl-consort-checklist\\] as well as considering baseline values of the outcome variable in the analysis, but it has been shown recent meta-analysis, that most rigouros methodological designs showed lowest treatment effects<sup>e.g.\\ [11](#ref-holperModeratorsSexualRecidivism2024)</sup>.\n",
    "\n",
    "In einem wesentlichen Punkt gelang es uns jedoch nicht die Vorgaben der CODC umzusetzen, da die Studie undersamplet ist. Pro Studienarm hätten 214 Probanden eingeschlossen werden müssen, um auch kleine effektstärken bis d = 0.2 entdeckt werden können. Dies gelang nicht. Auch gelang es nicht, eine repräsentative Stichprobe der Gesamtheit aller Sexualstraftäter in bewährungshilfe zu erheben, da kein uneingeschränkter Zugang zu den klienten möglich war. Dies ist umso bedauerlicher, da es sich um eine bundesweite Stichprobe aus fast allen Bundesländern Deutschlands handelt. Der fehlende direkte Kontakt zu den Probanden führte überdies möglicherweise zu einer selektiven vorauswahl der probanden durch die Bewährungshelfer. Weiterhin konnte aus datenschutzgründen während der Durchführung der Therapie kein direkter Kontakt zu den probanden außerhalb der HBI aufgenommen werden. Dies war nur möglich über den Supervisor, so dass ein direktes nachfragen, wenn beispielsweise längere Zeit kein login erfolgte möglich war. dies könnte sich auch in den, im vergleich zur ursprünglich geplanten dauer der Teilnahme an der klinischen Studie niedergeschlagen haben. Der überwiegend größte Teil ader probanden schaffte es nicht, in der vorgegebenen Zeit die einzelnen Module abzuschließen, mit der konsequenz, dass letztlich der häufigste Ausschlussgrund in einem Ende der klinischen Studie lag. Trotz einer zusätzlichen verlängerung der projektlaufzeit um mehr als ein jahr war es nicht möglich, dasss alle eingeschlossenen Probanden die Teilnahme abschlossen. In letzter Konsequenz gelang es daher auch nicht, eine ausreichend große Stichprobe zu rekrutieren, so dass die Studie als undersampled betrachtet werden muss. Neben schwierigkeiten durch die Corona-Pandemie, gelang es trotz erheblichen rekrutierungsaufwands nicht die angestrebte stichprobengröße zu erreichen, so dass rückblickend klar gesagt werden muss, dass die Schätzungen der verfügbaren Fallzahlen zu optimistisch waren.\n",
    "\n",
    "Ein weiterer Grund für das Fehlen eines Effektes könnte auch sein, dass es sich in der Merheit der Stichprobe um low-risk Täter handelt. Es ist umstritten ob auch low-risk täter behandelt werden sollte \\[LIT: SOTP!\\], jedoch zeigte kürzliche Veröffentlichungen unter anderm im bereich der sekundären prävention, dass dies zu keinem erhöhten Risiko führt<sup>[60](#ref-franqueIndividualsVoluntaryTreatment2023)</sup>. Dennoch zeigte sich insbesondere in den sekundären endpoints, für die es normwerte gibt, dass unsere stichprobe sehr häufig oberhalb der norm liegt, so dass davon ausgegangen werden kann, dass der jeweilige Risikofaktor bei vielen Klienten nicht stark ausgeprägt war \\[Beispiele einfügen oder auf abbildungen verweisen, wenn ich sie denn noch erstelle mit der Vergleichsnorm\\].\n",
    "\n",
    "Dies führt zu einem weiteren Kritikpunkte: die HBI folgte nicht konsequent dem RNR-Ansatz, nur beispielsweise ein Modul (kognitive Verzerrungen) bot eine individualisierung des inhaltes an (und alle Übungen + Nachrichten waren individualisiert; nur automatische Nachrichten beispielsweise nach jedem abgeschlossenen gudied Task oder nach jedem abgeschlossenen Modul oder Sitzung erfolgt eine automatische nachricht -\\> unbedingt in prozess diagramm aufnehmen!). Alle anderen Modulinhalte wurden allen probanden gezeigt, unabhängig davon, ob der Risikofaktor bei einem Klienten vorlag, oder nicht. Dies ist ein klarare Verstoß gegen die RNR Prinzipien und Meta-analysen zeigten, dass diejenigen programme größere Effektstärken zeigen, die nur individuals mit hohem rückfallrisiko in die studie eingeschlossenen haben. Dieses vorgehen ist im Zeiten von personalknappheit auch aus finanziellen Gründen sinnvoll, jedoch bildet die Studie ein realistisches Bild der gegenwärtigen Lage ab: viele individuals mit geringem Risiko erhalten auch eine gerichtliche Therapieweisung, die umgesetzt werden muss. Und für diese Therapieweisung finden sie keine Therapeuten und in dieser Versorgungslücke greift unsere HBI an. Overall, n = 70 (32%) of the ITT sample received an external (f2f) treatment (psychotherapy or medical treatment), but the court ordered this for n = 124 (56%). Only n = 48 (38.71%) of all participants who have an ordered treatment also in fact received external treatment at enrolement, the majority (n = 76; 61.29%) not. This figure underlines the care gap for individuals who committed sexual offenses against children in Germany and their problems to be able to fullfill treatment ordered by court. On the other side, most participants had a low recidivism risk at baseline and it seems to be questionable if the ordered treatment by court is really necessary from an RNR model point of view. But it seems to be not unusual to provide treatment to low-risk sexual offenders in Germany as well as in Canada<sup>[61](#ref-frankeEfficacyOutpatientTreatment2021),[62](#ref-mcpheePracticeSurveyCanadian2025)</sup>. Hier könnte auch noch eine größere Dunkelziffer sein, da wir ja kein repräsentatives sample haben…. Auch die baseline characteristics zeigen, dass es sich um eine wenig psychisch belastete population handelt, wie sich anhand des PHQ-D zeigte. Auch der Baseline wert im WHO-5 zeigt ein hohes psychologisches Well-being. Dies steht jedoch im Widerspruch mit der bisherigen Literatur, die in der Regel eine starke psychische Belastung für Personen mit sexuellem Interesse an Kinder aufzeigen \\[LIT -\\> Jahnke etc.\\]. da es sich in unserer Studie aber nur um einen geringen prozentsatz mit einer Diagnose pädophile Störung handelt, scheint die studie zu zeigen, dass es dem Straftäter in der Bewährungshilfe nicht sos chlecht geht.\n",
    "\n",
    "Ein weiterer Erklrärungsansatz für das fehlen eines Effektes könnte auch darin liegen, dass das primäre outcome, dass zum gegenwärtigen zeitpunkt schon vorliegt, auf Selbstberichten basiert. Selbstberichte sind durchaus umstritten in unserem Bereich. Mögliche Tendenzen zur Antwortverzerrung wurden nicht erhoben, was einen major kritikpunkt an der studie darstellt, und verhindert einen potentiellen Einfluss von Antortverzerrungen in den Analysen zu berücksichtigen. Allerdings steht der Kritik an selbstberichten aufgrund potentieller Impression management eine zunehmende anzahl an studien gegenüber, die selbst-berichten auch hinsichtlich von kriminologischen Faktoren und Rückfallrisiken zu selbstauskünften zeigen<sup>für\\ einen\\ Überblick\\ siehe\\ [46](#ref-sonjaetzlerDevelopmentInitialValidationsubmitted)</sup>. Officially recorded reoffenses are generally considered the gold standard for primary outcome assessment in treatment programs for individuals who have sexually offended (LIT). However, official recidivism is a rather insensitive outcome measure for treatment effects because ecidivism rates are low overall, and many offenses remain undetected or unregistered, resulting in low statistical power. Moreover, there is a time lag between the manifestation of deviant behavior and its registration, leading to delayed outcome assessment. Finally, recidivism is a distal measure that provides no insight into the treatment processes of risk reduction. Therefore, several authors have emphasized the importance of examining within-treatment changes in risk factors associated with recidivism<sup>[18](#ref-mannAssessingRiskSexual2010),[63](#ref-olverEvaluatingChangeMen2020)</sup>. Des Weiteren ist der CARES ein durchaus neues Tool, dass noch so umfangreich evaluiert ist, insbesondere liegen noch keine Daten zum Zusammenhang zwischen CARES und offiziellen Rückfalldaten vor.\n",
    "\n",
    "Schließlich könnte auch die Placebo bedingung zu starke effekte hervorrufen, so dass kein unterschied zu sehen ist. so könnte man argumentieren, dass themen wie gesundes essen, gesunder schlaf und sport zu einem - im besten falle - zufriedenerem leben führen. genaus dies ist das ziel im GLM. Möglicherweise fördert die placebo bedingung genau das, was das GLM empfiehlt. Jedoch zeigen sich im WHO-5 keine effekte auf das psychologische wohlbefinden, der beste proxy für zufriedenheit, den wir erfasst haben.\n",
    "\n",
    "Die Tatsache, dass in Modul 3 die Impulskontrolle bei Placebo abnimmt zeigt, wie wichtig eine evaluation vor der Implementierung auch im forensischen Kontext sinn macht und auch notwendig ist. Beipielsweise sind ganz viele Onlineinterventionen online und werden stark beworben, jedoch liegt keine evaluation vor, so dass nicht sicher ist, ob möglicherwiese mehr Schaden als Gutes angerichtet wird. Die letzte arbeit des projekt dunkelfeldes könnte man in diese Richtung interpretieren!\n",
    "\n",
    "Adverse events…\\[nochmals mit Lätth et al. vergleichen und schauen, ob e andere Literatur gibt mit diesen Angaben (z.B. SOTP)!\\]\n",
    "\n",
    "Unfortunately, none of these statistically significant effects in self-reports reached clinically significance defined by the reliable change index (Jacobson and Truax (1991)). Therefore, the effectiveness of the web-based intervention is questionable.\n",
    "\n",
    "Harms: Seh wenige rückfälle, kein unterschied zwischen trial arms. keine unterschied bei psychological well-being\n",
    "\n",
    "\\[Einschätzung der Verschlechterung und der Verbesserungen in Placebo: nicht klinisch relevant, wie ja auch die anderen signifikanten Ergebnisse\\]\n",
    "\n",
    "Dauer zu Lange? In Bezug auf Dropouts eigentlich nicht, da Prevent it deutlich kürzer, aber leicht höhere Dropouts. In Bezug auf Empfehlungen zur Behandlung von Sexualstraftäter deutlich zu kurz. Und im Vergleich zu web-based intervention outside offender research viel zu lange.\n",
    "\n",
    "Bei secondary endpoints nur eine Woche nach dem Modul ende schon die post Messung: der Abstand ist möglicherweise zu gering um schon einen Effekt messen zu können.\n",
    "\n",
    "Was messen die Fragebögen eigentlich? Zusammenhang zwischen Fragebögen und Rückfall oft gering (Letzte meta-meta analyse), aber sie messen mit hoher wahrscheinlichkeit nur Aspekte der komplexeren Konstrukte Risikovariblen.\n",
    "\n",
    "The Discussion section should contain a full description and discussion of the context.\n",
    "\n",
    "• Start with a sentence summarising your main findings and move on to relate your results to your hypothesis and data previously published. Authors must either to report their own, up-to-date systematic review or cite a recent systematic review of other trials as part of a panel putting your research into context with existing evidence (see panel for details). No subheadings should be used in this section.\n",
    "\n",
    "• Discuss any controversies raised by this study: is sexual interest changeable? McPhail et al. (2020): Hinweis, aber in meta-amalyse keine studie mit adäquater Kontrollgruppe; das können wir nun zeigen, dass auch bei Kontrollgruppendesign eine reduktion möglich ist.\n",
    "\n",
    "• Discuss the representativeness of the study population, to help readers assess the applicability of the findings to their setting: Due to a possible volunteer-effect, the representativnes of the sample is questionable. On the other side, to the best of our knowledge, this is the first clinical trial in Germany recruiting participants from almost all federal states.\n",
    "\n",
    "• Consider possible underlying mechanisms for your findings: dropouts because no official document for court;\n",
    "\n",
    "• Suggest future research directions: comparison to f2f treatment directly or waitlist control;\n",
    "\n",
    "• State general interpretation of data in light of all evidence available, noting the clinical significance and effects on patient care and policy, expanding on the summary provided in your Research in context panel.\n",
    "\n",
    "Futere directions: the intervention is currently only available in German. Consequently, the web-based intervention can only be applied in German-speaking countries, which limits its international generalizability.\n",
    "\n",
    "Second, the study was underpowered to detect small changes. The a priori sample size estimation revelead that 214 participants are necessary in each trial arm in order to be able to detect also effects smaller than d \\< 0.2 which is in line with the recommendations of the the Collaborative Data Outcome Committee (CODC;<sup>[44](#ref-beechCollaborativeOutcomeData2007)</sup>). Since the proposed sample size has not been reached, there may be a small significant effect in the data we oversee.\n",
    "\n",
    "Also problematic in this context is the high dropout rate of ??%. Aber nicht so hoch wie bei Prevent it, oder?\n",
    "\n",
    "Third, the sample cannot be considered representative oder doch -\\>\\>\\>\\> offizielle Statistiken suchen!!!!!! offizielle statistiken gibt es nicht, es gibt nur jehle, da sind aber nur daten bis 2019 drin, die nicht den zuwachs an KiPo leuten abbildet. da wir die grundgesamtheit aller von den Bewährungshelfenden befragten Personen nicht kennen und kaum jemand den NPQ ausgefüllt hat, können wir einfach nicht wissen, wie repräsentativ die daten sind! Due to a potential volunteer effect, representativeness for the overall population of individuals who have committed child sexual abuse (CSA) or child sexual exploitation material (CSEM) offenses cannot be ensured. Die Probanden erhielten eine aufwandsentschädigung von 120 euro, die aber angesichts der mindestdauer der teilnahme in einen sehr geringen Stundenlohn mündet. Durch die probandenentschädigung war es jedenfalls nicht möglich, einen\n",
    "\n",
    "Fourth, no waiting-list control group and no face-to-face intervention arm were included. This limits interpretability in two respects. On the one hand, it remains unclear whether the placebo condition might have stronger effects than a waiting-list control group (see relevant literature). On the other hand, the absence of a face-to-face control group prevents conclusions about whether the web-based intervention produces effects comparable to traditional face-to-face interventions, as examined in previous meta-analyses.\n",
    "\n",
    "Seventh, no assessments of participants’ personal experiences were included. Unfortunately, no feedback was collected from participants regarding the usability of the web-based intervention and the app, nor regarding their subjective experiences during the intervention. This omission limits the evaluation of user acceptance and satisfaction. \\[ABER: UTAUT ist doch so etwas ähnliches; also die Artikel von Sonja hier rein?\\]\n",
    "\n",
    "Eight, no diagnostic was made by staff and therefore, psychiatric disorders only assessed by self reports.\n",
    "\n",
    "Ausschluss von recidivisten ist nicht so optimal aus klinischer sicht, denn diese hätte es am dringesten nötig\n",
    "\n",
    "@myTabu tries to minimize a potential volunteer-bias by providing an adequate allowance."
   ],
   "id": "adfbb2b0-5956-44ef-9910-0decc1195fe4"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- CONTRIBUTORS -->"
   ],
   "id": "eb7bc8b8-9794-4459-baac-3918f86077a5"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- Is automatically filled with metadata defined above; do not delete the shortcode -->"
   ],
   "id": "7d47db19-4571-4018-b1d1-490f57b710e2"
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<span class=\"contributors\">Contributors</span>\n",
    "\n",
    "PF: writing – original draft, visualization, conceptualization, funding acquisition, project administration, supervision, software, methodology. SSch: writing – review & editing, investigation. BS: writing – review & editing, investigation. AL: formal analysis, writing – review & editing. FK: formal analysis, writing – review & editing. LM: ST: writing – review & editing, investigation, conceptualization, funding acquisition. SH: writing – review & editing, conceptualization, funding acquisition. CB: KJ: writing – review & editing, project administration. MR: writing – review & editing. SE: writing – review & editing. AS: writing – review & editing, conceptualization, funding acquisition. PB: writing – review & editing, conceptualization, funding acquisition. JLM: writing – review & editing, conceptualization, funding acquisition, supervision."
   ],
   "id": "07bba7a3-131b-4c87-92ec-c938fcb56aa5"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- DATA SHARING -->"
   ],
   "id": "f4c3cf98-ac8e-4049-b696-d69b15ab4e57"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- Is automatically filled with metadata defined above; do not delete the shortcode -->"
   ],
   "id": "d5735533-62e7-4976-a106-5530aa8c2710"
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Data sharing\n",
    "\n",
    "The source code of the webbased intervention, the content of the intervention as well as placebo arm are available online under an open source licence after publishing. De-identified data will be made available on reasonable request from the corresponding author (peter.fromberger@medizin.uni-goettingen.de). Data access requests, which can be submitted via email to the corresponding author, must include a detailed description of the research question and aims. Data sharing will be authorised following proposal approval and the execution of a signed data access agreement, strictly for scientific use."
   ],
   "id": "01a2e41d-34d9-4277-9b4c-222494becf80"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- DECLARATION OF INTEREST -->"
   ],
   "id": "304befb8-3f34-4e48-8292-8bad91a1a819"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- Is automatically filled with metadata defined above; do not delete the shortcode -->"
   ],
   "id": "fc95170c-0240-4a22-955d-928ecae470d9"
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Declaration of interests\n",
    "\n",
    "PF: conflict-of-interest is here SSch: conflict-of-interest is here BS: conflict-of-interest is here AL: conflict-of-interest is here FK: conflict-of-interest is here LM: conflict-of-interest is here ST: conflict-of-interest is here SH: conflict-of-interest is here CB: conflict-of-interest is here KJ: conflict-of-interest is here MR: conflict-of-interest is here SE: conflict-of-interest is here AS: conflict-of-interest is here PB: conflict-of-interest is here. All other authors declare no competing interests."
   ],
   "id": "1b2c9a04-b999-47ee-bdc3-efe7e71149a3"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- ACKNOWLEDGEMENTS -->"
   ],
   "id": "e8ced8b6-1a9a-438c-94f7-dd1867adab29"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- Is automatically filled with metadata defined above; do not delete the shortcode -->"
   ],
   "id": "55d892c2-013f-4213-8cde-53112d71181d"
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Acknowledgement\n",
    "\n",
    "The work was funded by the German Federal Ministry of Education and Research (BMBF, Funding number: 01KR1807A). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The authors would like to thank all participants for their time, trust and willingness to take part in the study. Furthermore, we would like to thank all community supervisors for taking part in the study - the project as well as the clinical trial was only possible with their help and support. The authors are grateful to Matthias Koller, Andreas Hill und Sophie K. Piper for taking part in the DSMB. Our statement on the use of ai in the creation of the manuscript: - translation, correct grammar."
   ],
   "id": "6b5d357a-1c2d-4b43-a077-3e3107091e2d"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- ACKNOWLEDGEMENTS -->"
   ],
   "id": "a083bb2a-2b34-4b69-bb4a-f05f52fb9339"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- Is automatically filled; do not delete the shortcode -->"
   ],
   "id": "c499e46d-24a5-40d3-8414-629b705bc628"
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## References\n",
    "\n",
    "<span class=\"csl-left-margin\">1 </span><span class=\"csl-right-inline\">World Health Organization. [Responding to Children and Adolescents Who Have Been Sexually Abused: WHO Clinical Guidelines](https://www.ncbi.nlm.nih.gov/pubmed/29630189). Geneva: World Health Organization, 2017.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">2 </span><span class=\"csl-right-inline\">Piolanti A, Schmid IE, Fiderer FJ, Ward CL, Stöckl H, Foran HM. [Global Prevalence of Sexual Violence Against Children: A Systematic Review and Meta-Analysis](https://doi.org/10.1001/jamapediatrics.2024.5326). *JAMA Pediatrics* 2025; **179**: 264–72.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">3 </span><span class=\"csl-right-inline\">Kewley S, Mhlanga-Gunda R, Van Hout M-C. [Preventing child sexual abuse before it occurs: Examining the scale and nature of secondary public health prevention approaches](https://doi.org/10.1080/13552600.2021.2000651). *Journal of Sexual Aggression* 2023; **29**: 1–33.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">4 </span><span class=\"csl-right-inline\">Seto MC, Roche K, Rodrigues NC, Curry S, Letourneau E. [Evaluating Child Sexual Abuse Perpetration Prevention Efforts: A Systematic Review](https://doi.org/10.1080/10538712.2024.2356194). *Journal of Child Sexual Abuse* 2024; **33**: 847–68.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">5 </span><span class=\"csl-right-inline\">Beier KM, Nentzl J, Von Heyden M, Fishere M, Amelung T. Preventing Child Sexual Abuse and the Use of Child Sexual Abuse Materials: Following up on the German Prevention Project Dunkelfeld. *Journal of Prevention* 2024; published online Sept. DOI:[10.1007/s10935-024-00792-0](https://doi.org/10.1007/s10935-024-00792-0).</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">6 </span><span class=\"csl-right-inline\">Baskurt S. A <span class=\"nocase\">Meta-analysis</span> of Recidivism Rates Among Individuals Who Commit Child Sexual Exploitation Material (CSEM) Offending. 2024. DOI:[10.22215/etd/2024-16307](https://doi.org/10.22215/etd/2024-16307).</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">7 </span><span class=\"csl-right-inline\">Garrington C, Kelty S, Rickwood D, Boer DP. [A conceptual framework for internet child abuse material offenders: Risk-relevant therapy based on assessed risk factors](https://doi.org/10.1080/13218719.2023.2251149). *Psychiatry, Psychology and Law* 2024; **31**: 1081–97.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">8 </span><span class=\"csl-right-inline\">König A. The German “Dunkelfeld” Approach: When the Dark Figure of Sexual Delinquency Against Minors Remains Shady. *Journal of Prevention* 2025; published online April. DOI:[10.1007/s10935-025-00852-z](https://doi.org/10.1007/s10935-025-00852-z).</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">9 </span><span class=\"csl-right-inline\">Beier KM, Von Heyden M, Nentzl J, Amelung T. Preventing Child Sexual Abuse in the “Dunkelfeld”: A Public Health Imperative Requiring Context-Appropriate Science—A Response to König (2025). *Journal of Prevention* 2025; published online June. DOI:[10.1007/s10935-025-00859-6](https://doi.org/10.1007/s10935-025-00859-6).</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">10 </span><span class=\"csl-right-inline\">Andrews DA, Bonta J. The Psychology of Criminal Conduct, 5th edn. New Providence, NJ: Lexis Nexis, 2010.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">11 </span><span class=\"csl-right-inline\">Holper L, Mokros A, Habermeyer E. [Moderators of Sexual Recidivism as Indicator of Treatment Effectiveness in Persons With Sexual Offense Histories: <span class=\"nocase\">An Updated Meta-analysis</span>](https://doi.org/10.1177/10790632231159071). *Sexual Abuse* 2024; **36**: 255–91.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">12 </span><span class=\"csl-right-inline\">Koehler J, Lösel F. [A meta-evaluative synthesis of the effects of custodial and community-based offender rehabilitation](https://doi.org/10.1177/14773708241256501). *European Journal of Criminology* 2025; **22**: 3–29.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">13 </span><span class=\"csl-right-inline\">Olver ME, Stockdale KC. [Sexual Offense Treatment Programming and Recidivism Reduction: A Meta-Meta-Analysis of Program Outcomes and Sources of Effect Size Heterogeneity](https://doi.org/10.1007/s11930-025-00409-5). *Current Sexual Health Reports* 2025; **17**: 13.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">14 </span><span class=\"csl-right-inline\">Schmucker M, Lösel F. [The effects of sexual offender treatment on recidivism: An international meta-analysis of sound quality evaluations](https://doi.org/10.1007/s11292-015-9241-z). *Journal of Experimental Criminology* 2015; **11**: 597–630.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">15 </span><span class=\"csl-right-inline\">Schmucker M, Lösel F. Sexual offender treatment for reducing recidivism among convicted sex offenders: A systematic review and meta-analysis. *Campbell Systematic Reviews* 2017; **13**. DOI:[10.4073/csr.2017.8](https://doi.org/10.4073/csr.2017.8).</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">16 </span><span class=\"csl-right-inline\">Gouveia C, Silva T, Cunha O, Seto MC, Maimone S, Caridade S. A Systematic Review on the Effectiveness of Interventions for Individuals Who Have Committed Online Sexual Crimes Involving Children. *Psychosocial Intervention* 2025; **25**. DOI:[10.5093/pi2025a16](https://doi.org/10.5093/pi2025a16).</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">17 </span><span class=\"csl-right-inline\">Seto MC, Augustyn C, Roche KM, Hilkes G. [Empirically-based dynamic risk and protective factors for sexual offending](https://doi.org/10.1016/j.cpr.2023.102355). *Clinical Psychology Review* 2023; **106**: 102355.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">18 </span><span class=\"csl-right-inline\">Mann RE, Hanson RK, Thornton D. [Assessing Risk for Sexual Recidivism: Some Proposals on the Nature of Psychologically Meaningful Risk Factors](https://doi.org/10.1177/1079063210366039). *Sexual Abuse* 2010; **22**: 191–217.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">19 </span><span class=\"csl-right-inline\">Babchishin KM, Merdian HL, Bartels RM, Perkins D. [Child Sexual Exploitation Materials Offenders: A Review](https://doi.org/10.1027/1016-9040/a000326). *European Psychologist* 2018; **23**: 130–43.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">20 </span><span class=\"csl-right-inline\">Reichel R, Daser A, Gnielka FM, Schmidt AF, Blokland A, Lehmann RJB. [A review of risk factors for online and mixed child sexual abuse material offending: What is being researched?](https://doi.org/10.1080/13552600.2024.2418100) *Journal of Sexual Aggression* 2024; : 1–44.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">21 </span><span class=\"csl-right-inline\">Seto MC. [The Motivation-Facilitation Model of Sexual Offending](https://doi.org/10.1177/1079063217720919). *Sexual Abuse* 2019; **31**: 3–24.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">22 </span><span class=\"csl-right-inline\">Babchishin KM, Dibayula S, McCulloch C, Hanson RK, Helmus LM. [ACUTE-2007 and STABLE-2007 predict recidivism for men adjudicated for child sexual exploitation material offending.](https://doi.org/10.1037/lhb0000540) *Law and Human Behavior* 2023; **47**: 606–18.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">23 </span><span class=\"csl-right-inline\">Schmidt A, Niehaus S. Outpatient Therapists’ Perspectives on Working With Persons Who Are Sexually Interested in Minors. *Archives of Sexual Behavior* 2022; published online Aug. DOI:[10.1007/s10508-022-02377-6](https://doi.org/10.1007/s10508-022-02377-6).</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">24 </span><span class=\"csl-right-inline\">Stiels-Glenn M. The availability of outpatient psychotherapy for paedophiles in Germany. *Recht Psychiatr* 2010; **28**: 74–80.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">25 </span><span class=\"csl-right-inline\">Beier KM, Grundmann D, Kuhle LF, Scherner G, Konrad A, Amelung T. [The German Dunkelfeld Project: A Pilot Study to Prevent Child Sexual Abuse and the Use of Child Abusive Images](https://doi.org/10.1111/jsm.12785). *The Journal of Sexual Medicine* 2015; **12**: 529–42.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">26 </span><span class=\"csl-right-inline\">Hillert J, Haubrock LS, Dekker A, Briken P. [Web-Based Initiatives to Prevent Sexual Offense Perpetration: A Systematic Review](https://doi.org/10.1007/s11920-024-01489-1). *Current Psychiatry Reports* 2024; **26**: 121–33.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">27 </span><span class=\"csl-right-inline\">Wild TSN, Fromberger P, Jordan K, Müller I, Müller JL. [Web-Based Health Services in Forensic Psychiatry: A Review of the Use of the Internet in the Treatment of Child Sexual Abusers and Child Sexual Exploitation Material Offenders](https://doi.org/10.3389/fpsyt.2018.00763). *Frontiers in Psychiatry* 2019; **9**: 763.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">28 </span><span class=\"csl-right-inline\">Crocamo C, Palpella D, Cavaleri D, *et al.* [Digital health interventions for mental health disorders: An umbrella review of meta-analyses of randomised controlled trials](https://doi.org/10.1016/j.landig.2025.100878). *The Lancet Digital Health* 2025; **7**: 100878.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">29 </span><span class=\"csl-right-inline\">Baumeister H, Reichler L, Munzinger M, Lin J. [The impact of guidance on internet-based mental health interventions–a systematic review](https://doi.org/10.1016/j.invent.2014.08.003). *Internet Interv* 2014; **1**: 205–15.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">30 </span><span class=\"csl-right-inline\">Heber E, Ebert DD, Lehr D, Cuijpers P, Berking M, Nobis S. The benefit of web-and computer-based interventions for stress: A systematic review and meta-analysis. *Journal of medical Internet research* 2017; **19:e32**.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">31 </span><span class=\"csl-right-inline\">Cowpertwait L, Clarke D. [Effectiveness of web-based psychological interventions for depression: A meta-analysis](https://doi.org/10.1007/s11469-012-9416-z). *Int J Mental Health* 2013; **11**: 247–68.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">32 </span><span class=\"csl-right-inline\">Lehr D, Heber E, Sieland B, Hillert A, Funk B, Ebert DD. [Occupational <span class=\"nocase\">eMental</span> health and teachers’ health: A meta-analytic review on the efficacy of internet-based intervention for promoting mental health in teachers](https://doi.org/10.1007/s11553-016-0541-6). *Präv Gesundheit* 2016; **11**: 182–92.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">33 </span><span class=\"csl-right-inline\">Richards D, Richardson T. [Computer-based psychological treatments for depression: A systematic review and meta-analysis](https://doi.org/10.1016/j.cpr.2012.02.004). *Clin Psychol Rev* 2012; **32**: 329–42.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">34 </span><span class=\"csl-right-inline\">Andersson G, Paxling B, Wiwe M, Vernmark K, Felix CB, Lundborg L. [Therapeutic alliance in guided internet-delivered cognitive behavioural treatment of depression, generalized anxiety disorder and social anxiety disorder](https://doi.org/10.1016/j.brat.2012.05.003). *Behav Res Ther* 2012; **50**: 544–50.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">35 </span><span class=\"csl-right-inline\">Ebert DD, Hannig W, Tarnowski T, Sieland B, Götzky B, Berking M. [Web-based rehabilitation aftercare following inpatient psychosomatic treatment](https://doi.org/10.1055/s-0033-1345191). *Die Rehabil* 2013; **52**: 164–72.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">36 </span><span class=\"csl-right-inline\">Bengtsson J, Nordin S, Carlbring P. [Therapists’ experiences of conducting cognitive behavioural therapy online vis-à-vis face-to-face](https://doi.org/10.1080/16506073.2015.1053408). *Cogn Behav Ther* 2015; **44**: 470–9.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">37 </span><span class=\"csl-right-inline\">Schröder S, Bauer L, Müller JL, Briken P, Fromberger P, Tozdan S. [Web-Based Interventions for Individuals who Committed Sexual Offenses Against Children: Development, Evaluation, and Implementation](https://doi.org/10.1177/00938548221140351). *Criminal Justice and Behavior* 2023; **50**: 235–51.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">38 </span><span class=\"csl-right-inline\">Lätth J, Landgren V, McMahan A, *et al.* [Effects of internet-delivered cognitive behavioral therapy on use of child sexual abuse material: A randomized placebo-controlled trial on the Darknet](https://doi.org/10.1016/j.invent.2022.100590). *Internet Interventions* 2022; **30**: 100590.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">39 </span><span class=\"csl-right-inline\">Fromberger P, Schröder S, Bauer L, *et al.* [@<span class=\"nocase\">myTabu</span>—A Placebo Controlled Randomized Trial of a Guided Web-Based Intervention for Individuals Who Sexually Abused Children and Individuals Who Consumed Child Sexual Exploitation Material: A Clinical Study Protocol](https://doi.org/10.3389/fpsyt.2020.575464). *Frontiers in Psychiatry* 2021; **11**: 575464.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">40 </span><span class=\"csl-right-inline\">Hopewell S, Chan A-W, Collins GS, *et al.* [CONSORT 2025 statement: Updated guideline for reporting randomised trials](https://doi.org/10.1016/S0140-6736(25)00672-5). *The Lancet* 2025; **405**: 1633–40.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">41 </span><span class=\"csl-right-inline\">Briken P, Berner W, Flöter A, Jückstock V, von Franqué F. [Prävention sexuellen Kindesmissbrauchs im Dunkelfeld – das Hamburger Modell](https://doi.org/10.1055/s-0043-100462). *PSYCH up2date* 2017; **11**: 243–62.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">42 </span><span class=\"csl-right-inline\">Wild TSN, Müller I, Fromberger P, Jordan K, Klein L, Müller JL. [Prevention of Sexual Child Abuse: Preliminary Results From an Outpatient Therapy Program](https://doi.org/10.3389/fpsyt.2020.00088). *Frontiers in Psychiatry* 2020; **11**: 88.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">43 </span><span class=\"csl-right-inline\">Rollnick S, Miller WR, Arkowitz H. Motivational Interviewing in the Treatment of Psychological Problems, 2nd edn. New York, NY: Guilford Press, 2015.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">44 </span><span class=\"csl-right-inline\">Beech A, Bourgon G, Hanson R, *et al.* The Collaborative Outcome Data Committee’s Guidelines for the Evaluation of Sexual Offender Treatment Outcome Research Part 2: CODC Guidelines Collaborative Outcome Data Committee (in alphabetical order). 2007.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">45 </span><span class=\"csl-right-inline\">Nitsche K, Etzler S, Tröger A-S, Rettenberger M. Erfassung akut- und stabil-dynamischer Risikofaktoren sowie devianten und delinquenten Verhaltens bei Pädosexualität Manual zur Verwendung von Acute-SR, Stable-SR und CMC. Wiesbaden: Kriminologische Zentralstelle, 2022.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">46 </span><span class=\"csl-right-inline\">Sonja Etzler, Katharina Nitsche, Ann-Sophie Tröger, Peter Fromberger, Martin Rettenberger. Development and Initial Validation of the Child Sexual Abuse Risk Evaluation Self-Report (CARES) Scales: Assessment of Acute- and Stable-Dynamic Risk Factors via Self-Report in Individuals Convicted of Sexual Offenses Against Children. submitted; published online submitted.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">47 </span><span class=\"csl-right-inline\">Bech P. Measuring the Dimension of Psychological General Well-Being by the WHO-5. *Quality of Life Newsletter* 2004; **32**: 15–6.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">48 </span><span class=\"csl-right-inline\">Topp CW, Østergaard SD, Søndergaard S, Bech P. [The WHO-5 well-being index: A systematic review of the literature](https://doi.org/10.1159/000376585). *Psychother Psychosom* 2015; **84**: 167–76.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">49 </span><span class=\"csl-right-inline\">Horvath A. The development of the working alliance inventory. New York, NY: Guilford Press, 1986.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">50 </span><span class=\"csl-right-inline\">Horvath AO, Greenberg LS. Development and validation of the working alliance inventory. *J Counsel Psychol* 1989; **36**. DOI:[10.1037/0022-0167.36.2.223](https://doi.org/10.1037/0022-0167.36.2.223).</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">51 </span><span class=\"csl-right-inline\">Wilmers F, Munder T, Leonhart R, Herzog T, Plassmann R, Barth J. [Die deutschsprachige Version des Working Alliance Inventory-Short Revised (WAI-SR)-Ein schulenübergreifendes, ökonomisches und empirisch validiertes Instrument zur Erfassung der therapeutischen Allianz](https://doi.org/10.7892/boris.27962). *Klin Diagn Eval* 2008; **1**: 343–58.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">52 </span><span class=\"csl-right-inline\">Endres J, Oranu N. Fragebogen zu subjektiven Behandlungsvoraussetzungen. Für das Projekt: “Therapie mit Langstrafigen – Evaluationskonzept”. Straubing: Tagung der Sotha-Leiter, 2010.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">53 </span><span class=\"csl-right-inline\">Schröder S, Buntrock C, Neumann L, Müller JL, Fromberger P. [Acceptance of a Web-Based Intervention in Individuals Who Committed Sexual Offenses Against Children: Cross-Sectional Study](https://doi.org/10.2196/48880). *JMIR Formative Research* 2024; **8**: e48880.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">54 </span><span class=\"csl-right-inline\">Schröder S, Tozdan S, Briken P, Müller J, Fromberger P. Engagement in a web-based intervention for individuals who committed sexual offenses against children: Observational study. *BMC Psychology* 2025; **13**. DOI:[10.1186/s40359-025-02366-z](https://doi.org/10.1186/s40359-025-02366-z).</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">55 </span><span class=\"csl-right-inline\">R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2025.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">56 </span><span class=\"csl-right-inline\">Wolbers M, Noci A, Delmar P, Gower-Page C, Yiu S, Bartlett JW. [Standard and reference-based conditional mean imputation](https://doi.org/10.1002/pst.2234). *Pharmaceutical Statistics* 2022; **21**: 1246–57.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">57 </span><span class=\"csl-right-inline\">Brunner E, Munzel U. [The Nonparametric Behrens-Fisher Problem: Asymptotic Theory and a Small-Sample Approximation](https://doi.org/10.1002/(SICI)1521-4036(200001)42:1<17::AID-BIMJ17>3.0.CO;2-U). *Biometrical Journal* 2000; **42**: 17–25.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">58 </span><span class=\"csl-right-inline\">Fay MP, Brittain EH, Proschan MA. Pointwise confidence intervals for a survival distribution with small samples or heavy censoring. *Biostatistics* 2013; **14**: 723–36.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">59 </span><span class=\"csl-right-inline\">Fay MP, Proschan MA, Brittain E. [Combining One-Sample Confidence Procedures for Inference in the Two-Sample Case](https://doi.org/10.1111/biom.12231). *Biometrics* 2015; **71**: 146–56.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">60 </span><span class=\"csl-right-inline\">Franqué F, Bergner-Koether R, Schmidt S, *et al.* Individuals under voluntary treatment with sexual interest in minors: What risk do they pose? *Frontiers in Psychiatry* 2023; **14**. DOI:[10.3389/fpsyt.2023.1277225](https://doi.org/10.3389/fpsyt.2023.1277225).</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">61 </span><span class=\"csl-right-inline\">Franke I, Streb J, Leichauer K, Handke S, Dudeck M, Tippelt S. [Efficacy of outpatient treatment of sex offenders](https://doi.org/10.1016/j.ijlp.2021.101738). *International Journal of Law and Psychiatry* 2021; **79**: 101738.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">62 </span><span class=\"csl-right-inline\">McPhee P, Monaghan J, Stephens S. [A Practice Survey of Canadian Forensic Sexual Behavior Programs](https://doi.org/10.1177/10790632251377706). *Sexual abuse : a journal of research and treatment* 2025; : 10790632251377706.</span>\n",
    "\n",
    "<span class=\"csl-left-margin\">63 </span><span class=\"csl-right-inline\">Olver M, Stockdale K. Evaluating change in men who have sexually offended: Linkages to risk assessment and management. *Curr Psychiatry Rep* 2020; **22**. DOI:[10.1007/s11920-020-01146-3](https://doi.org/10.1007/s11920-020-01146-3).</span>"
   ],
   "id": "5ceff3ab-7db3-4870-9bb5-3bf729dc3dbc"
  },
  {
   "cell_type": "raw",
   "metadata": {
    "raw_mimetype": "text/html"
   },
   "source": [
    "<!-- YOUR SUPPLEMENTARY MATERIAL -->"
   ],
   "id": "91b76360-77cc-44f5-9b7e-ef1d5f9cb3e8"
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "\u000c\n",
    "\n",
    "## Supplementary Material\n",
    "\n",
    "Three words here."
   ],
   "id": "8fb84ec3-23d2-4aa2-82c7-266a8c199084"
  }
 ],
 "nbformat": 4,
 "nbformat_minor": 5,
 "metadata": {}
}
